<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2307233909
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Kolitarda
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROSUVASTATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        51.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ALPHA PHARMA INDUSTRY " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ALPHA PHARMA INDUSTRY 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2732]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Alpha Pharma Industry
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ALPHA PHARMA INDUSTRY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Kolitarda belongs to a group of medicines called statins.<br />You have been prescribed Kolitarda because:<br />&bull; You have a high cholesterol level. This means you are at<br />risk from a heart attack or stroke. Kolitarda is used in<br />adults, adolescents and children 6 years or older to treat<br />high cholesterol.<br />&bull; You have been advised to take a statin, because changing<br />your diet and doing more exercise were not enough to<br />correct your cholesterol levels. You should continue with<br />your cholesterol-lowering diet and exercise while you are<br />taking Kolitarda.<br />&bull; You have other factors that increase your risk of having a<br />heart attack, stroke or related health problems.<br />A disease called atherosclerosis can cause heart attack, stroke<br />and other problems. Atherosclerosis is due to build-up of fatty<br />deposits in your arteries.<br />Why it is important to keep taking Kolitarda<br />Kolitarda is used to correct the levels of fatty substances in the<br />blood called lipids, the most common of which is cholesterol.<br />There are different types of cholesterol found in the<br />blood &ndash; &lsquo;bad&rsquo; cholesterol (LDL-C) and &lsquo;good&rsquo; cholesterol<br />(HDL-C).<br />&bull; Kolitarda can reduce the &lsquo;bad&rsquo; cholesterol and increase the<br />&lsquo;good&rsquo; cholesterol.<br />&bull; It works by helping to block your body&rsquo;s production of &lsquo;bad&rsquo;<br />cholesterol. It also improves your body&rsquo;s ability to remove<br />it from your blood.<br />For most people, high cholesterol does not affect the way they<br />feel because it does not produce any symptoms. However, if it<br />is left untreated, fatty deposits can build up in the walls of your<br />blood vessels causing them to narrow.<br />Sometimes, these narrowed blood vessels can get blocked<br />which can cut off the blood supply to the heart or brain<br />leadling to a heart attack or a stroke. By lowering<br />your cholesterol levels, you can reduce your risk of having a<br />heart attack, a stroke or related health problems.<br />You need to keep taking Kolitarda, even if it has your<br />cholesterol to the right level, because it prevents your<br />cholesterol levels from creeping up again and causing<br />build-up of fatty deposits. However, you should stop if your<br />doctor tells you to do so, or you have become pregnant.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Kolitarda:<br />&bull; If you have ever had an allergic reaction to Kolitarda, or to<br />any of its ingredients (listed in section 6).<br />If you are pregnant or breast-feeding. If you become<br />pregnant while taking Kolitarda, stop taking it<br />immediately and tell your doctor. Women should avoid<br />becoming pregnant while taking Kolitarda by using<br />suitable contraception.<br />&bull; If you have liver disease.<br />&bull; If you have severe kidney problems.<br />&bull; If you have repeated or unexplained muscle aches or pains.<br />&bull; If you take a drug combination of sofosbuvir/velpatasvir/<br />voxilaprevir (used for viral infection of the liver called<br />hepatitis C).<br />&bull; If you take a drug called ciclosporin (used, for example,<br />after organ transplants).<br />If any of the above applies to you (or you are in doubt), please<br />go back and see your doctor.<br />In addition, do not take 40 mg (the highest dose):<br />&bull; If you have moderate kidney problems (if in doubt, please<br />ask your doctor).<br />&bull; If your thyroid gland is not working properly.<br />&bull; If you have had any repeated or unexplained muscle<br />aches or pains, a personal or family history of muscle<br />problems, or a previous history of muscle problems when<br />taking other cholesterol-lowering medicines.<br />&bull; If you regularly drink large amounts of alcohol.<br />&bull; If you are of Asian origin (Japanese, Chinese, Filipino,<br />Vietnamese, Korean and Indian).<br />&bull; If you take other medicines called fibrates to lower your<br />cholesterol.<br />If any of the above applies to you (or you are in doubt),<br />please go back and see your doctor.<br />Warnings and precautions:<br />Talk to your doctor or pharmacist before taking Kolitarda.<br />&bull; If you have problems with your kidneys.<br />&bull; If you have problems with your liver.<br />&bull; If you have had repeated or unexplained muscle aches or<br />pains, a personal or family history of muscle problems, or<br />a previous history of muscle problems when taking other<br />cholesterol-lowering medicines. Tell your doctor<br />immediately if you have unexplained muscle aches or<br />pains, especially if you feel unwell or have a fever. Also,<br />tell your doctor or pharmacist if you have a muscle<br />weakness that is constant.<br />&bull; If you have ever developed a severe skin rash or skin<br />peeling, blistering and/or mouth sores after taking<br />Kolitarda or other related medicines.<br />&bull; If you regularly drink large amounts of alcohol.<br />&bull; If your thyroid gland is not working properly.<br />&bull; If you take other medicines called fibrates to lower your<br />cholesterol. Please read this leaflet carefully, even if you<br />have taken other medicines for high cholesterol before.<br />&bull; If you take medicines used to treat the HIV infection e.g.<br />ritonavir with lopinavir and/or atazanavir, please see<br />&ldquo;Other medicines and Kolitarda&rdquo;.<br />&bull; If you are taking or have taken in the last 7 days a<br />medicine called fusidic acid (a medicine for bacterial<br />infection), orally or by injection. The combination of<br />fusidic acid and Kolitarda can lead to serious muscle<br />problems (rhabdomyolysis), please see &ldquo;Other medicines<br />and Kolitarda&rdquo;.<br />&bull; If you are over 70 (as your doctor needs to choose the right<br />start dose of Kolitarda to suit you)<br />If any of the above applies to you (or if you are not sure):<br />&bull; Do not take 40 mg (the highest dose) and check with your<br />doctor or pharmacist before you actually start taking any<br />dose of Kolitarda.<br />Serious skin reactions including Stevens-Johnson syndrome<br />and drug reaction with eosinophilia and systemic symptoms<br />(DRESS) have been reported in association with Kolitarda<br />treatment. Stop using Kolitarda and seek medical attention<br />immediately if you notice any of the symptoms described in<br />section 4.<br />In a small number of people, statins can affect the liver. This<br />is identified by a simple test which looks for increased levels<br />of liver enzymes in the blood. For this reason, your doctor will<br />usually carry out this blood test (liver function test) before and<br />during treatment with Kolitarda.&nbsp;While you are on this medicine your doctor will monitor<br />you closely if you have diabetes or are at risk of developing<br />diabetes. You are likely to be at risk of developing diabetes<br />if you have high levels of sugars and fats in your blood, are<br />overweight and have high blood pressure.<br />Children and adolescents<br />&bull; If the patient is under 6 years old: Kolitarda should not be<br />given to children younger than 6 years.<br />&bull; If the patient is below 18 years of age: 40 mg tablet is not<br />suitable for use in children and adolescents below 18 years<br />of age.<br />Other medicines and Kolitarda:<br />Tell your doctor or pharmacist if you are taking, have recently<br />taken or might take any other medicines, including medicines<br />obtained without a prescription.<br />Tell your doctor if you are taking any of the following:<br />&bull; ciclosporin (used for example, after organ transplants)<br />&bull; warfarin or clopidogrel (or any other drug used for thinning<br />the blood)<br />&bull; fibrates (such as gemfibrozil, fenofibrate) or any other<br />medicine used to lower cholesterol (such as ezetimibe)<br />indigestion remedies (used to neutralise acid in your<br />stomach)<br />&bull; erythromycin (an antibiotic), fusidic acid<br />(an antibiotic &ndash; please see below and Warnings and<br />precautions)<br />&bull; an oral contraceptive (the pill)<br />&bull; regorafenib (used to treat cancer)<br />&bull; darolutamide (used to treat cancer)<br />&bull; hormone replacement therapy<br />&bull; any of the following drugs used to treat viral infections,<br />including HIV or hepatitis C infection, alone or in<br />combination (please see Warnings and precautions):<br />ritonavir, lopinavir, atazanavir, sofosbuvir, voxilaprevir,<br />ombitasvir, paritaprevir, dasabuvir, velpatasvir, grazoprevir,<br />elbasvir, glecaprevir, pibrentasvir.<br />The effects of these medicines could be changed by Kolitarda<br />or they could change the effect of Kolitarda.<br />If you need to take oral fusidic acid to treat a bacterial<br />infection you will need to temporarily stop using this<br />medicine. Your doctor will tell you when it is safe to restart<br />Kolitarda. Taking Kolitarda with fusidic acid may rarely lead<br />to muscle weakness, tenderness or pain (rhabdomyolysis).<br />See more information regarding rhabdomyolysis in Section 4.<br />Kolitarda with food and drink<br />You can take Kolitarda with or without food.<br />Pregnancy, breastfeeding and fertility:<br />Do not take Kolitarda tablets if you are pregnant or<br />breast-feeding. If you become pregnant while taking Kolitarda<br />tablets stop taking it immediately and tell your doctor. Women<br />should avoid becoming pregnant while taking Kolitarda tablets<br />by using suitable contraception. Ask your doctor or pharmacist<br />for advice before taking any medicine.<br />Driving and using machines:<br />Most people can drive a car and operate machinery while<br />using Kolitarda &ndash; it will not affect their ability. However, some<br />people feel dizzy during treatment with Kolitarda. If you feel<br />dizzy, consult your doctor before attempting to drive or use<br />machines.<br />Kolitarda contains lactose or any other ingredient:<br />If you have been told by your doctor that you have an<br />intolerance to some sugars (lactose or milk sugar), contact<br />your doctor before taking Kolitarda. For a full list of<br />ingredients, please see Contents of the pack and other<br />information.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine as your doctor has told you. Check<br />with your doctor or pharmacist if you are not sure.<br />Usual doses in adults<br />If you are taking Kolitarda for high cholesterol:<br />Starting dose<br />Your treatment with Kolitarda tablets must start with the 5<br />mg or the 10 mg dose, even if you have taken a higher dose<br />of a different statin before. The choice of your start dose will<br />depend upon:<br />&bull; Your cholesterol level.<br />&bull; The level of risk you have of experiencing a heart attack<br />or stroke.<br />&bull; Whether you have a factor that may make you more<br />sensitive to possible side effects.<br />Please check with your doctor or pharmacist which start dose<br />of Kolitarda tablets will best suit you.<br />Your doctor may decide to give you the lowest dose (5 mg) if:<br />&bull; You are of Asian origin (Japanese, Chinese, Filipino,<br />Vietnamese, Korean and Indian).<br />&bull; You are over 70 years of age.<br />&bull; You have moderate kidney problems.<br />&bull; You are at risk of muscle aches and pains (myopathy).<br />Increasing the dose and maximum daily dose<br />Your doctor may decide to increase your dose. This is so that<br />you are taking the amount of Kolitarda that is right for you.<br />If you started with a 5 mg dose, your doctor may decide to<br />double this to 10 mg, then 20 mg and then 40 mg if necessary.<br />If you started on 10 mg, your doctor may decide to double this<br />to 20 mg and then 40 mg if necessary. There will be a gap of<br />four weeks between every dose adjustment.<br />The maximum daily dose is 40 mg. It is only for patients with<br />high cholesterol levels and a high risk of heart attacks or stroke<br />whose cholesterol levels are not lowered enough with 20 mg.<br />If you are taking Kolitarda to reduce your risk of having a<br />heart attack, stroke or related health problems:<br />The recommended dose is 20 mg daily. However, your doctor<br />may decide to use a lower dose if you have any of the factors<br />mentioned above.<br />Use in children and adolescents aged 6-17 years<br />The dose range in children and adolescents aged 6 to 17 years<br />is 5 to 20 mg once daily. The usual start dose is 5 mg per day,<br />and your doctor may gradually increase your dose to find the<br />right amount of Kolitarda for you. The maximum daily dose of<br />Kolitarda is 10 or 20 mg for children aged 6 to 17 years<br />depending on your underlying condition being treated. Take<br />your dose once a day. Children should not use 40 mg Dose.<br />Taking your tablets<br />Swallow each tablet whole with a drink of water.<br />Take Kolitarda once daily. You can take it at any time of the<br />day with or without food.<br />Try to take your tablet at the same time every day to help you<br />to remember it.<br />Regular cholesterol checks<br />It is important to go back to your doctor for regular cholesterol<br />checks, to make sure your cholesterol has reached and is<br />staying at the correct level.<br />Your doctor may decide to increase your dose so that you are<br />taking the amount of Kolitarda that is right for you.<br />If you take more Kolitarda than you should<br />Contact your doctor or nearest hospital for advice. If you go<br />into hospital or receive treatment for another condition, tell<br />the medical staff that you&rsquo;re taking Kolitarda.<br />If you forget to take Kolitarda<br />Don&rsquo;t worry, just take your next scheduled dose at the correct<br />time. Do not take a double dose to make up for a forgotten<br />dose.<br />If you stop taking Kolitarda<br />Talk to your doctor if you want to stop taking Kolitarda. Your<br />cholesterol levels might increase again if you stop taking<br />Kolitarda.<br />If you have any further questions on the use of this medicine,<br />ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects,<br />although not everybody gets them.<br />It is important that you are aware of what these side effects<br />may be. They are usually mild and disappear after a short time.&nbsp;Stop taking Kolitarda and seek medical help immediately if<br />you have any of the following allergic reactions:<br />&bull; Difficulty in breathing, with or without swelling of the face,<br />lips, tongue and/or throat.<br />&bull; Swelling of the face, lips, tongue and/or throat, which may<br />cause difficulty in swallowing.<br />&bull; Severe itching of the skin (with raised lumps).<br />&bull; Reddish non-elevated, target-like or circular patches on<br />the trunk, often with central blisters, skin peeling, ulcers<br />of mouth, throat, nose, genitals and eyes. These serious<br />skin rashes can be preceded by fever and flu-like symptoms<br />(Stevens-Johnson syndrome).<br />&bull; Widespread rash, high body temperature and enlarged<br />lymph nodes (DRESS syndrome or drug hypersensitivity<br />syndrome).<br />Also, stop taking Kolitarda and talk to your doctor<br />immediately:<br />&bull; If you have any unusual aches or pains in your muscles<br />which go on for longer than you might expect. Muscle<br />symptoms are more common in children and adolescents<br />than in adults. As with other statins, a very small number<br />of people have experienced unpleasant muscle effects<br />and rarely these have gone on to become a potentially life<br />threatening muscle damage known as rhabdomyolysis.<br />&bull; If you experience muscle rupture.<br />&bull; If you have lupus-like disease syndrome (including rash,<br />joint disorders and effects on blood cells).<br />Common possible side effects (these may affect between 1<br />in 10 and 1 in 100 patients):<br />&bull; Headache, stomach pain, constipation, feeling sick, muscle<br />pain, feeling weak, dizziness.<br />&bull; An increase in the amount of protein in the urine - this<br />usually returns to normal on its own without having to stop<br />taking your Kolitarda tablets (only 40 mg).<br />&bull; Diabetes. This is more likely if you have high levels of<br />sugars and fats in your blood, are overweight and have<br />high blood pressure. Your doctor will monitor you while<br />you are taking this medicine.<br />Uncommon possible side effects (these may affect between 1<br />in 100 and 1 in 1,000 patients):<br />&bull; Rash, itching or other skin reactions.<br />&bull; An increase in the amount of protein in the urine - this<br />usually returns to normal on its own without having to stop<br />taking your Kolitarda tablets (10 mg and 20 mg).<br />Rare possible side effects (these may affect between 1 in<br />1,000 and 1 in 10,000 patients):<br />&bull; Severe allergic reaction &ndash; signs include swelling of the face,<br />lips, tongue and/or throat, difficulty in swallowing and<br />breathing, a severe itching of the skin (with raised lumps).<br />If you think you are having an allergic reaction, then stop<br />taking Kolitarda and seek medical help immediately.<br />&bull; Muscle damage in adults &ndash; as a precaution, stop taking<br />Kolitarda and talk to your doctor immediately if you have<br />any unusual aches or pains in your muscles which go on for<br />longer than expected.<br />&bull; A severe stomach pain (inflamed pancreas).<br />&bull; Increase in liver enzymes in the blood.<br />&bull; Bleeding or bruising more easily than normal due to low<br />level of blood platelets.<br />&bull; Lupus-like disease syndrome (including rash, joint<br />disorders and effects on blood cells).<br />Very rare possible side effects (these may affect less than 1<br />in 10,000 patients):<br />&bull; Jaundice (yellowing of the skin and eyes), hepatitis (an<br />inflamed liver), traces of blood in your urine, damage to<br />the nerves of your legs and arms (such as numbness), joint<br />pain, memory loss and breast enlargement in men<br />(gynaecomastia).<br />Side effects of unknown frequency may include:<br />&bull; Diarrhoea (loose stools), cough, shortness of breath,<br />oedema (swelling), sleep disturbances, including insomnia<br />and nightmares, sexual difficulties, depression, breathing<br />problems, including persistent cough and/or shortness of<br />breath or fever, tendon injury and muscle weakness that<br />is constant.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist.<br />This includes any possible side effects not listed in this leaflet.<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />&bull; The National Pharmacovigilance Centre (NPC)<br />&bull; Fax: +966-11-205-7662<br />&bull; SFDA Call Center: 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa<br />&bull; Other GCC States:<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of the sight and reach of children<br />and in original packages<br />&bull; Do not use this medicine after the expiry date, which is<br />stated on the carton, and blister after &lsquo;EXP&rsquo;. The expiry date<br />refers to the last day of that month.<br />&bull; Do not store above 30&deg;C<br />&bull; Do not throw away any medicines via wastewater or<br />household waste. Ask your pharmacist how to throw away<br />medicines you no longer use. These measures will help<br />protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Kolitarda contains<br />&bull; The active substance is rosuvastatin.<br />&bull; Kolitarda 10mg Film-coated Tablets<br />&bull; Each tablet contains 10 mg of rosuvastatin.<br />&bull; Kolitarda 20mg Film-coated Tablets<br />&bull; Each tablet contains 20 mg of rosuvastatin.<br />&bull; The other ingredients are:<br />&bull; Tablet core: lactose monohydrate, microcrystalline<br />cellulose, crospovidone, tricalcium phosphate anhydrous<br />granular, magnesium stearate, and purified water<br />&bull; Tablet coat: Oprady Pink</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Kolitarda 10 mg film-coated tablets are pink colored, round
shaped, biconvex film-coated tablets engraved “JS21” on one
side & plain on the other side.
Kolitarda 20 mg film-coated tablets are pink colored, round
shaped, biconvex film-coated tablets engraved “JS20” on one
side & plain on the other side.
Kolitarda 10 mg film-coated tablets and Kolitarda 20 mg
film-coated tablets are available in pack containing 30 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Alpha Pharma,<br />King Abdullah Economic city, Kingdom of Saudi Arabia<br />Tel: +966 12 21 29013<br />Email: regulatory@alphapharma.com.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي كوليتاردا إلى مجموعة أدوية تسمى الستاتين.<br />لقد وصف لك كوليتاردا للأسباب التالية:<br />&bull;لديك ارتفاع في مستوى الكوليسترول. هذا يعني أنك معرض<br />لخطر الإصابة بنوبة قلبية أو سكتة دماغية. يستخدم كوليتاردا في<br />البالغين والمراهقين والأطفال 6 سنوات أو أكبر لعاج ارتفاع نسبة<br />الكوليسترول في الدم.<br />&bull;لقد تم نصحك بتناول الستاتين، لأن تغيير نظامك الغذائي وممارسة<br />المزيد من التمارين لم يكن كافيين لتصحيح مستويات الكوليسترول<br />في الدم. يجب أن تستمر في نظامك الغذائي لخفض الكوليسترول<br />وممارسة الرياضة أثناء تناولك كوليتاردا.<br />&bull;لديك عوامل أخرى تزيد من خطر إصابتك بنوبة قلبية أو سكتة دماغية<br />أو مشاكل صحية ذات صلة.<br />&bull;يمكن أن يسبب المرض بما يسمى بتصلب الشرايين، نوبة قلبية<br />وسكتة دماغية ومشاكل أخرى. يحدث تصلب الشرايين بسبب<br />تراكم الترسبات الدهنية في الشرايين.<br />لماذا من المهم الاستمرار في تناول كوليتاردا<br />يستخدم كوليتاردا لتصحيح مستويات المواد الدهنية في الدم والتي تسمى<br />الدهون ، وأشهرها الكولسترول.<br />توجد أنواع مختلفة من الكوليسترول في الدم - الكوليسترول &quot;السيء&quot;<br />)البروتين الشحمي المنخفض الكثافة( والكوليسترول &quot;الجيد&quot; )البروتين<br />الشحمي المرتفع الكثافة(.<br />&bull;يستطيع كوليتاردا تقليل الكوليسترول &quot;الضار&quot; وزيادة الكوليسترول<br />&quot;الجيد&quot;.<br />&bull;يعمل من خال المساعدة على منع الجسم من إنتاج الكوليسترول<br />&quot;الضار&quot;. كما أنه يحسن قدرة جسمك على إزالته من دمك.<br />بالنسبة لمعظم الناس ، لا يؤثر ارتفاع الكوليسترول في الطريقة التي<br />يشعرون بها لأنه لا ينتج عنه أي أعراض. ومع ذلك ، إذا تركته دون<br />عاج ، يمكن أن تتراكم الترسبات الدهنية في جدران الأوعية الدموية<br />مما يؤدي إلى تضييقها.<br />في بعض الأحيان، يمكن أن تنسد هذه الأوعية الدموية الضيقة مما قد<br />يؤدي إلى قطع إمداد الدم إلى القلب أو الدماغ مما يؤدي إلى نوبة<br />قلبية أو سكتة دماغية. عن طريق خفض مستويات الكوليسترول لديك<br />، يمكنك تقليل خطر الإصابة بنوبة قلبية أو سكتة دماغية أو مشاكل<br />صحية ذات صلة.<br />تحتاج إلى الاستمرار في تناول كوليتاردا، حتى لو كان يحتوي على<br />نسبة الكوليسترول في الدم إلى المستوى الصحيح ، لأنه يمنع مستويات<br />الكوليسترول في الدم من الارتفاع مرة أخرى ويسبب تراكم الترسبات<br />الدهنية. ومع ذلك ، يجب أن تتوقف إذا طلب منك طبيبك القيام بذلك،<br />أو إذا أصبحت حاماً.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول كوليتاردا:<br />&bull;إذا كان لديك أي رد فعل تحسسي في أي وقت مضى عند اخذك<br />.) كوليتاردا، أو أي من مكوناته )المدرجة في القسم 6<br />&bull;إذا كنت حاما أو مرضعة. إذا أصبحت حاماً أثناء تناول كوليتاردا<br />، توقفي عن تناوله فورًا وأخبري طبيبك. يجب على النساء تجنب<br />الحمل أثناء تناول كوليتاردا باستخدام وسائل منع الحمل المناسبة<br />&bull;إذا كان لديك مرض في الكبد.<br />&bull;إذا كنت تعاني من مشاكل خطيرة في الكلى.<br />&bull;إذا كنت تعاني من آلام أو آلام متكررة أو غير مبررة في العضلات.<br />&bull;إذا كنت تتناول مجموعة دواء من سوفوسبوفير / فيلباتاسفير /<br />فوكسيلابريفير )تستخدم للعدوى الفيروسية في الكبد تسمى التهاب<br />الكبد ج(.<br />&bull;إذا كنت تتناول دواء يسمى سيكلوسبورين )يستخدم ، على سبيل<br />المثال ، بعد عمليات زرع الأعضاء(.<br />إذا انطبق عليك أي مما ورد أعاه )أو إذا كنت في شك( ، فيرجى<br />الرجوع والاطاع على طبيبك.<br />بالإضافة إلى ذلك ، لا تتناول 40 ملجم )أعلى جرعة(:<br />&bull;إذا كنت تعاني من مشاكل متوسطة في الكلى )إذا كان لديك شك ،<br />فيرجى استشارة طبيبك(.<br />&bull;إذا كانت غدتك الدرقية لا تعمل بشكل صحيح.<br />&bull;إذا كان لديك أي آلام أو آلام متكررة أو غير مبررة في العضات،<br />أو تاريخ شخصي أو عائلي من مشاكل العضات ، أو تاريخ سابق<br />من مشاكل العضات عند تناول أدوية أخرى لخفض الكوليسترول.<br />&bull;إذا كنت تشرب كميات كبيرة من الكحول بانتظام.<br />&bull;إذا كنت من أصل آسيوي )ياباني ، صيني ، فلبيني ، فيتنامي ،<br />كوري وهندي(.<br />&bull;إذا كنت تتناول أدوية أخرى تسمى الفايبرات لخفض نسبة<br />الكوليسترول لديك.<br />إذا انطبق عليك أي مما ورد أعاه )أو إذا كنت في شك( ، فيرجى<br />الرجوع والاطاع إلى طبيبك.<br />الاحتياطات والتحذيرات<br />تحدث إلى طبيبك أو الصيدلي قبل تناول كوليتاردا.<br />&bull;إذا كان لديك مشاكل في الكلى.<br />&bull;إذا كان لديك مشاكل في الكبد.<br />&bull;إذا كنت تعاني من آلام أو آلام متكررة أو غير مبررة في<br />العضات، أو لديك تاريخ شخصي أو عائلي من مشاكل العضات<br />، أو تاريخ سابق من مشاكل العضات عند تناول أدوية أخرى<br />لخفض الكوليسترول. أخبر طبيبك على الفور إذا كنت تعاني من<br />آلام أو آلام عضلية غير مبررة ، خاصة إذا كنت تشعر بتوعك أو<br />تعاني من الحمى. أخبر طبيبك أو الصيدلي أيضًا إذا كنت تعاني<br />من ضعف دائم في العضات.<br />&bull;إذا أصبت في أي وقت مضى بطفح جلدي شديد أو تقشر جلدي و /<br />أو تقرحات و / أو تقرحات في الفم بعد تناول كوليتاردا أو الأدوية<br />الأخرى ذات الصلة.<br />&bull;إذا كنت تشرب كميات كبيرة من الكحول بانتظام.<br />&bull;إذا كانت غدتك الدرقية لا تعمل بشكل صحيح.<br />&bull;إذا كنت تتناول أدوية أخرى تسمى الفايبرات لخفض نسبة<br />الكوليسترول لديك. يرجى قراءة هذه النشرة بعناية ، حتى لو<br />كنت قد تناولت أدوية أخرى لارتفاع نسبة الكوليسترول في الدم<br />من قبل.<br />&bull;إذا كنت تتناول أدوية لعاج عدوى فيروس نقص المناعة البشرية،<br />على سبيل المثال: ريتونافير مع لوبينافير و / أو أتازانافير، يرجى<br />مراجعة &quot;الأدوية الأخرى وكوليتاردا&quot;.<br />&bull;إذا كنت تتناول أو تناولت في الأيام السبعة الماضية دواء يسمى<br />حمض الفوسيديك )دواء للعدوى البكتيرية( ، عن طريق الفم أو<br />عن طريق الحقن. يمكن أن يؤدي الجمع بين حمض الفوسيديك<br />كوليتاردا إلى مشاكل عضلية خطيرة )انحال الربيدات( ، يرجى<br />الاطاع على &quot;أدوية أخرى كوليتاردا&quot;.<br />&bull;إذا كان عمرك أكثر من 70 عامًا )حيث يحتاج طبيبك إلى اختيار<br />جرعة البدء الصحيحة من كوليتاردا التي تناسبك(<br />&bull;إذا كنت تعاني من قصور حاد في الجهاز التنفسي.<br />&bull;إذا كنت من أصل آسيوي - أي اليابانية والصينية والفلبينية<br />والفيتنامية والكورية والهندية. يحتاج طبيبك إلى اختيار جرعة<br />البداية الصحيحة من كوليتاردا التي تناسبك.<br />إذا كان أي مما سبق ينطبق عليك )أو إذا لم تكن متأكدًا(:<br />&bull;لا تأخذ 40 ملجم )أعلى جرعة( واستشر طبيبك أو الصيدلي قبل أن<br />تبدأ فعليًا في تناول أي جرعة من كوليتاردا.<br />تم الإباغ عن تفاعات جلدية خطيرة بما في ذلك متلازمة<br />ستيفنز جونسون والتفاعل الدوائي مع فرط الحمضات والأعراض<br />الجهازية بالاشتراك مع عاج كوليتاردا. توقف عن استخدام<br />كوليتاردا واطلب العناية الطبية فورًا إذا لاحظت أيًا من الأعراض<br />. الموضحة في القسم 4<br />في عدد قليل من الأشخاص ، يمكن أن تؤثر الستاتين المخفضة<br />للكوليسترول على الكبد. يتم تحديد ذلك من خال اختبار بسيط<br />يبحث عن زيادة مستويات إنزيمات الكبد في الدم. لهذا السبب ،</p><p>سيقوم طبيبك عادة بإجراء فحص الدم هذا )اختبار وظائف الكبد(<br />قبل وأثناء العاج مع كوليتاردا.<br />أثناء تناولك لهذا الدواء ، سيراقبك طبيبك عن كثب إذا كنت مصابًا<br />بداء السكري أو معرض للإصابة بمرض السكري. من المحتمل<br />أن تكون معرضًا لخطر الإصابة بمرض السكري إذا كان لديك<br />مستويات عالية من السكريات والدهون في دمك ، وتعاني من<br />زيادة الوزن وارتفاع ضغط الدم.<br />الأطفال والمراهقون<br />&bull;يجب عدم إعطاء كوليتاردا للأطفال الذين تقل أعمارهم عن 6<br />سنوات.<br />40 ملجم غير مناسب للأطفال والمراهقين الذين تقل أعمارهم &bull;<br />عن 18 سنة.<br />أدوية اخرى وكوليتاردا:<br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول<br />أي أدوية أخرى<br />أخبر طبيبك إذا كنت تتناول أيًا مما يلي:<br />&bull;سيكلوسبورين )يستخدم على سبيل المثال ، بعد زراعة الأعضاء(<br />&bull;وارفارين أو كلوبيدوجريل )أو أي دواء آخر يستخدم لتسييل الدم(<br />&bull;الفايبريت )مثل جمفيبروزيل ، فينوفايبرات( أو أي دواء آخر يستخدم<br />لخفض الكوليسترول )مثل إيزيتيميب(<br />&bull;علاجات عسر الهضم )تستخدم لتحييد الأحماض في معدتك(<br />&bull;إريثروميسين )مضاد حيوي( ، حمض الفوسيديك )مضاد حيوي -<br />يرجى الاطاع أدناه والتحذيرات والاحتياطات(<br />&bull;موانع الحمل الفموية )حبوب منع الحمل(<br />&bull;ريجورافينيب )يستخدم لعلاج السرطان(<br />&bull;دارولوتاميد )يستخدم لعلاج السرطان(<br />&bull;العلاج بالهرمونات البديلة<br />&bull;أي من الأدوية التالية المستخدمة لعاج العدوى الفيروسية ، بما في<br />ذلك عدوى فيروس نقص المناعة البشرية أو التهاب الكبد سي ،<br />بمفردها أو مجتمعة )يرجى الاطاع على التحذيرات والاحتياطات(:<br />ريتونافير ، لوبينافير ، أتازانافير ، سوفوسبوفير ، فوكسيلابريفير ،<br />أومبيتاسفير ، باريتابريفير ، داسابوفير ، فيلباتاسفير ، غرازابوفير ،<br />الباسفير ، جليكابريفير ، بيبرنتاسفير.<br />&bull;يمكن أن يغير كوليتاردا تأثير هذه الأدوية أو يمكن أن يغير هذه<br />الاأدوية تأثير كوليتاردا.<br />إذا كنت بحاجة إلى تناول حمض الفوسيديك عن طريق الفم لعاج<br />عدوى بكتيرية ، فستحتاج إلى التوقف عن استخدام هذا الدواء مؤقتًا.<br />سيخبرك طبيبك عندما يكون من الآمن إعادة استخدام كوليتاردا. نادرا<br />ما يؤدي تناول كوليتاردا بحمض الفوسيديك إلى ضعف العضات<br />أو الألم )انحال الربيدات(. انظر المزيد من المعلومات حول انحال<br />. الربيدات في القسم 4<br />كوليتاردا مع الطعام و الشراب:<br />يمكنك تناول كوليتاردا مع الطعام أو بدونه.<br />الحمل والرضاعة<br />لا تأخذ أقراص كوليتاردا إذا كنت حاماً أو مرضعة. إذا أصبحت حاماً<br />أثناء تناول أقراص كوليتاردا ، توقفي عن تناولها على الفور وأخبري<br />طبيبك. يجب على النساء تجنب الحمل أثناء تناول أقراص كوليتاردا<br />باستخدام وسائل منع الحمل المناسبة. اسأل طبيبك أو الصيدلي للحصول<br />على المشورة قبل تناول أي دواء.<br />القيادة واستخدام الالات:<br />يمكن لمعظم الناس قيادة السيارة وتشغيل الآلات أثناء استخدام كوليتاردا<br />- لن يؤثر ذلك على قدرتهم. ومع ذلك ، يشعر بعض الأشخاص بالدوار<br />أثناء العاج بكوليتاردا. إذا شعرت بالدوار ، استشر طبيبك قبل محاولة<br />القيادة أو استخدام الآلات.<br />يحتوي كوليتاردا على اللاكتوز أو أي مكون آخر:<br />إذا أخبرك طبيبك أنك لا تتحمل بعض السكريات )اللاكتوز أو سكر<br />الحليب( ، فاتصل بطبيبك قبل تناول كوليتاردا. للحصول على قائمة<br />كاملة بالمكونات ، يرجى الاطاع على محتويات العبوة ومعلومات<br />أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول هذا الدواء دائمًا كما أخبرك طبيبك. استشر طبيبك أو الصيدلي<br />إذا لم تكن متأكدًا.<br />الجرعات المعتادة عند البالغين<br />إذا كنت تتناول كوليتاردا لارتفاع نسبة الكوليسترول في الدم:<br />جرعة البدء<br />يجب أن يبدأ علاجك بأقراص كوليتاردا بجرعة 5 ملجم أو 10 ملجم ،<br />حتى لو كنت قد تناولت جرعة أعلى من ستاتين مختلف من قبل. يعتمد<br />اختيار جرعة البدء على:<br />&bull;مستوى الكوليسترول لديك.<br />&bull;مستوى خطورة تعرضك لنوبة قلبية أو سكتة دماغية.<br />&bull;ما إذا كان لديك عامل قد يجعلك أكثر حساسية للآثار الجانبية<br />المحتملة.<br />&bull;يرجى مراجعة طبيبك أو الصيدلي لمعرفة الجرعة التي تبدأ من<br />أقراص كوليتاردا تناسبك بشكل أفضل.<br />قد يقرر طبيبك إعطائك أقل جرعة ) 5 ملجم( إذا:<br />&bull;أن تكون من أصل آسيوي )ياباني ، صيني ، فلبيني ، فيتنامي ،<br />كوري وهندي(.<br />&bull;عمرك أكثر من 70 سنة.<br />&bull;لديك مشاكل متوسطة في الكلى.<br />&bull;أنت معرض لخطر الإصابة بأوجاع وآلام في العضات )اعتال<br />عضلي(.<br />زيادة الجرعة والجرعة اليومية القصوى<br />قد يقرر طبيبك زيادة جرعتك. هذا حتى تأخذ كمية كوليتاردا المناسبة<br />لك. إذا بدأت بجرعة 5 ملجم ، فقد يقرر طبيبك مضاعفة هذه الجرعة<br />إلى 10 ملجم ، ثم 20 ملجم ثم 40 ملجم إذا لزم الأمر. إذا بدأت<br />بجرعة 10 ملجم ، فقد يقرر طبيبك مضاعفة ذلك إلى 20 ملجم ثم<br />40 ملجم إذا لزم الأمر. ستكون هناك فجوة لمدة أربعة أسابيع بين كل<br />تعديل للجرعة.<br />الجرعة اليومية القصوى 40 ملجم. إنه مخصص فقط للمرضى<br />الذين يعانون من ارتفاع مستويات الكوليسترول في الدم وخطر<br />الإصابة بالنوبات القلبية أو السكتة الدماغية الذين لا تنخفض مستويات<br />الكوليسترول لديهم بشكل كافٍ مع 20 ملجم.<br />إذا كنت تتناول كوليتاردا لتقليل خطر الإصابة بنوبة قلبية أو سكتة دماغية<br />أو مشاكل صحية ذات صلة:<br />الجرعة الموصى بها هي 20 ملجم يومياً. ومع ذلك ، قد يقرر طبيبك<br />استخدام جرعة أقل إذا كان لديك أي من العوامل المذكورة أعاه.<br />17 سنة - استخدم في الأطفال والمراهقين الذين تتراوح أعمارهم بين 6<br />تتراوح الجرعة عند الأطفال والمراهقين الذين تتراوح أعمارهم بين<br />6 إلى 17 عامًا من 5 إلى 20 ملجم مرة واحدة يوميًا. جرعة البدء<br />المعتادة هي 5 ملجم في اليوم ، وقد يزيد طبيبك جرعتك تدريجياً للعثور<br />على الكمية المناسبة من كوليتاردا لك. الحد الأقصى للجرعة اليومية<br />من كوليتاردا هو 10 أو 20 ملجم للأطفال الذين تتراوح أعمارهم بين 6<br />إلى 17 عامًا اعتمادًا على حالتك الأساسية التي يتم علاجها. خذ جرعتك<br />مرة واحدة في اليوم. يجب على الأطفال عدم استخدام جرعة 40 ملجم.<br />أخذ أقراصك<br />ابتلع كل قرص كاملًًا مع الماء.<br />تناول كوليتاردا مرة واحدة يومياً. يمكنك تناوله في أي وقت من اليوم<br />مع أو بدون طعام.<br />حاول أن تأخذ دوائك في نفس الوقت كل يوم لمساعدتك على تذكره.<br />فحوصات الكوليسترول المنتظمة<br />من المهم العودة إلى طبيبك لإجراء فحوصات الكوليسترول المنتظمة<br />، للتأكد من وصول الكوليسترول لديك وبقائه عند المستوى الصحيح.<br />قد يقرر طبيبك زيادة جرعتك حتى تأخذ كمية كوليتاردا المناسبة لك.<br />إذا أخذت كوليتاردا أكثر مما ينبغي<br />اتصل بطبيبك أو أقرب مستشفى للحصول على المشورة. إذا ذهبت<br />إلى المستشفى أو تلقيت علاجًا لحالة أخرى ، فأخبر الطاقم الطبي أنك<br />تتناول كوليتاردا.<br />إذا نسيت أن تأخذ كوليتاردا<br />لا تقلق، فقط خذ جرعتك المجدولة التالية في الوقت الصحيح. لا تأخذ<br />جرعة مضاعفة لتعويض الجرعة المنسية.<br />إذا توقفت عن تناول كوليتاردا<br />تحدث إلى طبيبك إذا كنت تريد التوقف عن تناول كوليتاردا. قد ترتفع<br />مستويات الكوليسترول مرة أخرى إذا توقفت عن تناول كوليتاردا.<br />إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك<br />أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارًا جانبية ، على<br />الرغم من عدم حدوثها لدى الجميع.<br />من المهم أن تكون على دراية بما قد تكون عليه هذه الآثار الجانبية.<br />عادة ما تكون خفيفة وتختفي بعد وقت قصير.<br />توقف عن تناول كوليتاردا واطلب المساعدة الطبية على الفور إذا كان لديك<br />أي من ردود الفعل التحسسية التالية:<br />&bull;صعوبة في التنفس ، مع أو بدون تورم في الوجه والشفتين<br />واللسان و / أو الحلق.<br />&bull;انتفاخ الوجه والشفتين واللسان و / أو الحلق مما قد يسبب صعوبة<br />في البلع.<br />&bull;حكة شديدة في الجلد )مع نتوءات بارزة(.<br />&bull;بقع حمراء غير مرتفعة ، شبيهة بالهدف أو دائرية على الجذع،&nbsp;</p><p>غالبًا مع ظهور بثور مركزية ، وتقشير الجلد ، وتقرحات في الفم،<br />والحلق، والأنف، والأعضاء التناسلية والعينين. يمكن أن تسبق هذه<br />الطفح الجلدي الشديد الحمى وأعراض تشبه أعراض الأنفلونزا<br />)متلازمة ستيفنز جونسون(.<br />&bull;انتشار الطفح الجلدي وارتفاع درجة حرارة الجسم وتضخم الغدد<br />الليمفاوية )متلازمة دريس أو متلازمة فرط الحساسية للأدوية(.<br />توقف أيضًا عن تناول كوليتاردا وتحدث إلى طبيبك فورًا:<br />&bull;إذا كنت تعاني من أي آلام أو آلام غير عادية في عضلاتك تستمر<br />لفترة أطول مما تتوقع. تشيع أعراض العضات لدى الأطفال<br />والمراهقين أكثر من البالغين. كما هو الحال مع العقاقير المخفضة<br />للكوليسترول الأخرى، عانى عدد قليل جدًا من الأشخاص من<br />تأثيرات عضلية مزعجة ونادرًا ما تحولت إلى تلف عضلي<br />محتمل يهدد الحياة يُعرف باسم انحال الربيدات.<br />&bull;إذا كنت تعاني من تمزق العضلات.<br />&bull;إذا كنت تعاني من متلازمة مرض شبيه بمرض الذئبة )بما في<br />ذلك الطفح الجلدي واضطرابات المفاصل وتأثيرات على خلايا<br />الدم(.<br />الآثار الجانبية الشائعة المحتملة )قد تؤثر على ما بين 1 في 10 و 1 من<br />كل 100 معالج(:<br />&bull;صداع ، آلام في المعدة ، إمساك ، غثيان ، ألم عضلي ، شعور<br />بالضعف ، دوار.<br />&bull;زيادة كمية البروتين في البول - عادة ما يعود هذا إلى طبيعته<br />من تلقاء نفسه دون الحاجة إلى التوقف عن تناول جرعة 40<br />ملجم فقط(.<br />&bull;داء السكري. تزداد احتمالية حدوث ذلك إذا كان لديك مستويات<br />عالية من السكريات والدهون في الدم ، وتعاني من زيادة الوزن<br />وارتفاع ضغط الدم. سيراقبك طبيبك أثناء تناولك لهذا الدواء.<br />أعراض جانبية محتملة غير شائعة )قد تؤثر على ما بين 1 في 100 و 1<br />من كل 1000 مريض(:<br />&bull;طفح جلدي أو حكة أو تفاعلات جلدية أخرى.<br />&bull;زيادة كمية البروتين في البول - عادة ما يعود هذا إلى طبيعته من<br />تلقاء نفسه دون الحاجة إلى التوقف عن تناول أقراص كوليتاردا<br />)فقط كوليتاردا 10 ملجم و 20 ملجم(.<br />أعراض جانبية نادرة محتملة )قد تؤثر على ما بين 1 في 1000 و 1 من<br />10000 مريض(:<br />&bull;رد فعل تحسسي شديد - تشمل العلامات تورم في الوجه ، والشفتين<br />، واللسان و / أو الحلق ، وصعوبة في البلع والتنفس، وحكة شديدة<br />في الجلد )مع نتوءات مرتفعة(. إذا كنت تعتقد أنك تعاني من<br />رد فعل تحسسي ، فتوقف عن تناول كوليتاردا واطلب المساعدة<br />الطبية على الفور.<br />&bull;تلف العضات عند البالغين - كإجراء احترازي ، توقف عن تناول<br />كوليتاردا وتحدث إلى طبيبك على الفور إذا كان لديك أي آلام أو<br />آلام غير عادية في عضلاتك تستمر لفترة أطول من المتوقع.<br />&bull;آلام شديدة في المعدة )التهاب البنكرياس(.<br />&bull;زيادة إنزيمات الكبد في الدم.<br />&bull;حدوث نزيف أو كدمات بسهولة أكبر من المعتاد بسبب انخفاض<br />مستوى الصفيحات الدموية.<br />&bull;متلازمة المرض الشبيهة بالذئبة )بما في ذلك الطفح الجلدي<br />واضطرابات المفاصل وتأثيراتها على خلايا الدم(.<br />أعراض جانبية محتملة نادرة جدًا )قد تؤثر على أقل من 1 من بين<br />10000 معالج(:<br />&bull;اليرقان )اصفرار الجلد والعينين( والتهاب الكبد )التهاب الكبد(<br />وآثار الدم في البول وتلف أعصاب ساقيك وذراعيك )مثل التنميل(<br />وآلام المفاصل وفقدان الذاكرة وتضخم الثدي لدى الرجال )تثدي<br />الرجل(.<br />قد تشمل الآثار الجانبية التي لا تعرف شيوعها ما يلي:<br />&bull;الإسهال )براز رخو( ، والسعال ، وضيق التنفس ، والوذمة<br />)التورم( ، واضطرابات النوم ، بما في ذلك الأرق والكوابيس ،<br />والصعوبات الجنسية ، والاكتئاب ، ومشاكل التنفس ، بما في ذلك<br />السعال المستمر و / أو ضيق التنفس أو الحمى ، وإصابة الأوتار<br />والعضات ضعف ثابت.<br />للإبلاغ عن الأعراض الجانبية:<br />إذا ظهرت لديك أي آثار جانبية ، تحدث إلى طبيبك أو الصيدلي. يتضمن<br />ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة.<br />للإبلاغ عن أي آثار جانبية:<br />&bull;المملكة العربية السعودية:<br />المركز الوطني للتيقظ الدوائي<br />+966-11-205- &bull; فاكس 7662<br />&bull; الهاتف الموحد: 19999<br />npc.drug@sfda.gov.sa : &bull; البريد الالكتروني<br />https://ade.sfda.gov.sa : &bull; الموقع الإلكتروني<br />&bull;دول مجلس التعاون الخليجي الأخرى:<br />الرجاء الاتصال بالمؤسسات والهيئات الوطنية لكل دولة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull;يحفظ هذا الدواء بعيدا عن مرأى ومتناول الأطفال.<br />&bull;لا تتناول هذا الدواء بعد تاريخ انتهاء صلاحيته المطبوع على<br />العلبة أو الشريطة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم<br />في ذلك الشهر.<br />&bull;يخزن في عبوته الأصلية لحفظه من الضوء والرطوبة.<br />&bull;يحفظ في درجة حرارة لا تزيد عن 30 درجة مئوية.<br />&bull;لا تتناول هذا الدواء إذا لاحظت علامات تشوه العبوة أو علامات<br />تمزق للعبوة.<br />&bull;يجب عدم إلقاء أي أدوية في مياه الصرف الصحي أو في النفايات<br />المنزلية. وعليك أن تسأل الصيدلي عن كيفية التخلص من الأدوية<br />التي لا تحتاجها. وهذه التدابير تساعد على حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ماذا يحتوي كوليتاردا<br />&bull;المادة الفعالة هي رسوفاستاتين.<br />&bull;أقراص كوليتاردا 10 ملجم المغلفة.<br />&bull;يحتوي كل قرص على 10 ملجم من الرسوفاستاتين.<br />&bull;أقراص كوليتاردا 20 ملجم المغلفة.<br />&bull;يحتوي كل قرص على 20 ملجم من الرسوفاستاتين.<br />&bull;المكونات الأخرى هي:<br />&bull;داخل القرص: لاكتوز وحيد التميّة، مايكروكريستالين<br />سيليلوز، كروسبوفيدون، ذرات الفوسفات ثلاثية الكالسيوم<br />اللامائية، سترات المغنيسيوم، ماء مُنَقّى.<br />&bull;غلاف القرص: اوبرادي وردي</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص كوليتاردا 10 ملجم المغلفة قرص دائري<br />ثنائي التحدب مغطى بطبقة رقيقة، ذو اللون الوردي،<br />على أحد جانبيه. &raquo;JS21&raquo; منقوش<br />أقراص كوليتاردا 20 ملجم المغلفة قرص دائري<br />ثنائي التحدب مغطى بطبقة رقيقة، ذو اللون الوردي،<br />على أحد جانبيه. &raquo;JS20&raquo; منقوش<br />تتوفر أقراص كوليتاردا 10 ملجم المغلفة و كوليتاردا 20<br />ملجم المغلفة في عبوات تحتوي على 30 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>ألفا فارما<br />مدينة الملك عبد الله الإقتصادية، المملكة العربية السعودية<br />+966 12 21 هاتف: 29013<br />regulatory@alphapharma.com.sa : البريد الإلكترون</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                KOLITARDA 10 mg Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                KOLITARDA 10mg Film-coated Tablets, each tablet contains 10 mg of rosuvastatin. 
Excipient with known effect
Each film-coated tablet contains lactose (as monohydrate), see section 4.4.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                KOLITARDA 10 mg Film-coated Tablets
Pink colored, round shaped, biconvex film-coated tablets engraved “JS21” on one side & plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Treatment of hypercholesterolemia</u></em></p><p>Adults, adolescents and children aged 6 years or older with primary hypercholesterolemia (type IIa including heterozygous familial hypercholesterolemia) or mixed dyslipidemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.</p><p>Adults, adolescents and children aged 6 years or older with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.</p><p><em><u>Prevention of Cardiovascular Events</u></em></p><p>Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event (see section 5.1), as an adjunct to correction of other risk factors.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Before treatment initiation the patient should be placed on a standard cholesterol-lowering diet that should continue during treatment. The dose should be individualized according to the goal of therapy and patient response, using current consensus guidelines.</p><p><u>Treatment of hypercholesterolemia</u></p><p>The recommended start dose is 5 or 10 mg orally once daily in both statins na&iuml;ve or patients switched from another HMG CoA reductase inhibitor. The choice of start dose should take into account the individual patient&#39;s cholesterol level and future cardiovascular risk as well as the potential risk for adverse reactions (see below). A dose adjustment to the next dose level can be made after 4 weeks, if necessary (see section 5.1). In light of the increased reporting rate of adverse reactions with the 40 mg dose compared to lower doses (see section 4.8), a final titration to the maximum dose of 40 mg should only be considered in patients with severe hypercholesterolemia at high cardiovascular risk (in particular those with familial hypercholesterolemia), who do not achieve their treatment goal on 20 mg, and in whom routine follow-up will be performed (see section 4.4). Specialist supervision is recommended when the 40 mg dose is initiated.</p><p><u>Prevention of cardiovascular events</u></p><p>In the cardiovascular events risk reduction study, the dose used was 20 mg daily (see section 5.1).</p><p><u>Pediatric population</u></p><p>Pediatric use should only be carried out by specialists.</p><p>Children and adolescents 6 to 17 years of age (Tanner Stage &lt;II-V)</p><p><em>Heterozygous familial hypercholesterolemia</em></p><p>In children and adolescents with heterozygous familial hypercholesterolaemia the usual start dose is 5 mg daily.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In children 6 to 9 years of age with heterozygous familial hypercholesterolaemia, the usual dose range is 5-10 mg orally once daily. Safety and efficacy of doses greater than 10 mg have not been studied in this population.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In children 10 to 17 years of age with heterozygous familial hypercholesterolaemia, the usual dose range is 5-20 mg orally once daily. Safety and efficacy of doses greater than 20 mg have not been studied in this population.</p><p>Titration should be conducted according to the individual response and tolerability in pediatric patients, as recommended by the pediatric treatment recommendations (see section 4.4). Children and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment.</p><p><em>Homozygous familial hypercholesterolaemia</em></p><p>In children 6 to 17 years of age with homozygous familial hypercholesterolaemia, the recommended maximum dose is 20 mg once daily.</p><p>A starting dose of 5 to 10 mg once daily depending on age, weight and prior statin use is advised. Titration to the maximum dose of 20 mg once daily should be conducted according to the individual response and tolerability in pediatric patients, as recommended by the pediatric treatment recommendations (see section 4.4). Children and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment.</p><p>There is limited experience with doses other than 20 mg in this population.</p><p>The 40 mg tablet is not suitable for use in pediatric patients.</p><p><em>Children younger than 6 years</em></p><p>The safety and efficacy of use in children younger than 6 years has not been studied. Therefore, KOLITARDA&nbsp;&nbsp; is not recommended for use in children younger than 6 years.</p><p><u>Use in the elderly</u></p><p>A start dose of 5 mg is recommended in patients &gt;70 years (see section 4.4). No other dose adjustment is necessary in relation to age.</p><p><u>Dosage in patients with renal insufficiency</u></p><p>No dose adjustment is necessary in patients with mild to moderate renal impairment. The recommended start dose is 5 mg in patients with moderate renal impairment (creatinine clearance &lt;60 ml/min). The 40 mg dose is contraindicated in patients with moderate renal impairment. The use of KOLITARDA&nbsp;&nbsp; in patients with severe renal impairment is contraindicated for all doses (see sections 4.3 and 5.2).</p><p><u>Dosage in patients with hepatic impairment</u></p><p>There was no increase in systemic exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, increased systemic exposure has been observed in subjects with Child-Pugh scores of 8 and 9 (see section 5.2). In these patients an assessment of renal function should be considered (see section 4.4). There is no experience in subjects with Child-Pugh scores above 9. KOLITARDA&nbsp;&nbsp; is contraindicated in patients with active liver disease (see section 4.3).</p><p><u>Race</u></p><p>Increased systemic exposure has been seen in Asian subjects (see sections 4.3, 4.4 and 5.2). The recommended start dose is 5 mg for patients of Asian ancestry. The 40 mg dose is contraindicated in these patients.</p><p><u>Genetic polymorphisms</u></p><p>Specific types of genetic polymorphisms are known that can lead to increased rosuvastatin exposure (see section 5.2). For patients who are known to have such specific types of polymorphisms, a lower daily dose of KOLITARDA&nbsp;&nbsp; is recommended.</p><p><u>Dosage in patients with pre-disposing factors to myopathy</u></p><p>The recommended start dose is 5 mg in patients with predisposing factors to myopathy (see section 4.4).</p><p>The 40 mg dose is contraindicated in some of these patients (see section 4.3).</p><p><u>Concomitant therapy</u></p><p>Rosuvastatin is a substrate of various transporter proteins (e.g. OATP1B1 and BCRP). The risk of myopathy (including rhabdomyolysis) is increased when KOLITARDA&nbsp;&nbsp; is administered concomitantly with certain medicinal products that may increase the plasma concentration of rosuvastatin due to interactions with these transporter proteins (e.g. ciclosporin and certain protease inhibitors including combinations of ritonavir with atazanavir, lopinavir and/or tipranavir; see sections 4.4 and 4.5). Whenever possible, alternative medications should be considered, and, if necessary, consider temporarily discontinuing KOLITARDA&nbsp;&nbsp; therapy. In situations where co-administration of these medicinal products with KOLITARDA&nbsp;&nbsp; is unavoidable, the benefit and the risk of concurrent treatment and KOLITARDA&nbsp;&nbsp; dosing adjustments should be carefully considered (see section 4.5).</p><p><u>Method of Administration</u></p><p>KOLITARDA may be given at any time of day, with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Posology
Before treatment initiation the patient should be placed on a standard cholesterol-lowering diet that should continue during treatment. The dose should be individualized according to the goal of therapy and patient response, using current consensus guidelines.
Treatment of hypercholesterolemia
The recommended start dose is 5 or 10 mg orally once daily in both statins naïve or patients switched from another HMG CoA reductase inhibitor. The choice of start dose should take into account the individual patient's cholesterol level and future cardiovascular risk as well as the potential risk for adverse reactions (see below). A dose adjustment to the next dose level can be made after 4 weeks, if necessary (see section 5.1). In light of the increased reporting rate of adverse reactions with the 40 mg dose compared to lower doses (see section 4.8), a final titration to the maximum dose of 40 mg should only be considered in patients with severe hypercholesterolemia at high cardiovascular risk (in particular those with familial hypercholesterolemia), who do not achieve their treatment goal on 20 mg, and in whom routine follow-up will be performed (see section 4.4). Specialist supervision is recommended when the 40 mg dose is initiated.
Prevention of cardiovascular events
In the cardiovascular events risk reduction study, the dose used was 20 mg daily (see section 5.1).
Pediatric population
Pediatric use should only be carried out by specialists.
Children and adolescents 6 to 17 years of age (Tanner Stage <II-V)
Heterozygous familial hypercholesterolemia
In children and adolescents with heterozygous familial hypercholesterolaemia the usual start dose is 5 mg daily.
•	In children 6 to 9 years of age with heterozygous familial hypercholesterolaemia, the usual dose range is 5-10 mg orally once daily. Safety and efficacy of doses greater than 10 mg have not been studied in this population.
•	In children 10 to 17 years of age with heterozygous familial hypercholesterolaemia, the usual dose range is 5-20 mg orally once daily. Safety and efficacy of doses greater than 20 mg have not been studied in this population.
Titration should be conducted according to the individual response and tolerability in pediatric patients, as recommended by the pediatric treatment recommendations (see section 4.4). Children and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment.
Homozygous familial hypercholesterolaemia
In children 6 to 17 years of age with homozygous familial hypercholesterolaemia, the recommended maximum dose is 20 mg once daily.
A starting dose of 5 to 10 mg once daily depending on age, weight and prior statin use is advised. Titration to the maximum dose of 20 mg once daily should be conducted according to the individual response and tolerability in pediatric patients, as recommended by the pediatric treatment recommendations (see section 4.4). Children and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment.
There is limited experience with doses other than 20 mg in this population.
The 40 mg tablet is not suitable for use in pediatric patients.
Children younger than 6 years
The safety and efficacy of use in children younger than 6 years has not been studied. Therefore, KOLITARDA   is not recommended for use in children younger than 6 years.
Use in the elderly
A start dose of 5 mg is recommended in patients >70 years (see section 4.4). No other dose adjustment is necessary in relation to age.
Dosage in patients with renal insufficiency
No dose adjustment is necessary in patients with mild to moderate renal impairment. The recommended start dose is 5 mg in patients with moderate renal impairment (creatinine clearance <60 ml/min). The 40 mg dose is contraindicated in patients with moderate renal impairment. The use of KOLITARDA   in patients with severe renal impairment is contraindicated for all doses (see sections 4.3 and 5.2).
Dosage in patients with hepatic impairment
There was no increase in systemic exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, increased systemic exposure has been observed in subjects with Child-Pugh scores of 8 and 9 (see section 5.2). In these patients an assessment of renal function should be considered (see section 4.4). There is no experience in subjects with Child-Pugh scores above 9. KOLITARDA   is contraindicated in patients with active liver disease (see section 4.3).
Race
Increased systemic exposure has been seen in Asian subjects (see sections 4.3, 4.4 and 5.2). The recommended start dose is 5 mg for patients of Asian ancestry. The 40 mg dose is contraindicated in these patients.
Genetic polymorphisms
Specific types of genetic polymorphisms are known that can lead to increased rosuvastatin exposure (see section 5.2). For patients who are known to have such specific types of polymorphisms, a lower daily dose of KOLITARDA   is recommended.
Dosage in patients with pre-disposing factors to myopathy
The recommended start dose is 5 mg in patients with predisposing factors to myopathy (see section 4.4).
The 40 mg dose is contraindicated in some of these patients (see section 4.3).
Concomitant therapy
Rosuvastatin is a substrate of various transporter proteins (e.g. OATP1B1 and BCRP). The risk of myopathy (including rhabdomyolysis) is increased when KOLITARDA   is administered concomitantly with certain medicinal products that may increase the plasma concentration of rosuvastatin due to interactions with these transporter proteins (e.g. ciclosporin and certain protease inhibitors including combinations of ritonavir with atazanavir, lopinavir and/or tipranavir; see sections 4.4 and 4.5). Whenever possible, alternative medications should be considered, and, if necessary, consider temporarily discontinuing KOLITARDA   therapy. In situations where co-administration of these medicinal products with KOLITARDA   is unavoidable, the benefit and the risk of concurrent treatment and KOLITARDA   dosing adjustments should be carefully considered (see section 4.5).
Method of Administration
KOLITARDA may be given at any time of day, with or without food.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Renal Effects</u></p><p>Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with higher doses of KOLITARDA, in particular 40 mg, where it was transient or intermittent in most cases. Proteinuria has not been shown to be predictive of acute or progressive renal disease (see section 4.8). The reporting rate for serious renal events in post-marketing use is higher at the 40 mg dose. An assessment of renal function should be considered during routine follow-up of patients treated with a dose of 40 mg.</p><p><u>Skeletal Muscle Effects</u></p><p>Effects on skeletal muscle e.g. myalgia, myopathy and, rarely, rhabdomyolysis have been reported in KOLITARDA-treated patients with all doses and in particular with doses &gt; 20 mg. Very rare cases of rhabdomyolysis have been reported with the use of ezetimibe in combination with HMG-CoA reductase inhibitors. A pharmacodynamics interaction cannot be excluded (see section 4.5) and caution should be exercised with their combined use. As with other HMG-CoA reductase inhibitors, the reporting rate for rhabdomyolysis associated with KOLITARDA&nbsp;&nbsp; in post-marketing use is higher at the 40 mg dose.</p><p><em>Creatine Kinase Measurement</em></p><p>Creatine Kinase (CK) should not be measured following strenuous exercise or in the presence of a plausible alternative cause of CK increase which may confound interpretation of the result. If CK levels are significantly elevated at baseline (&gt;5xULN) a confirmatory test should be carried out within 5 &ndash; 7 days. If the repeat test confirms a baseline CK &gt;5xULN, treatment should not be started.</p><p><em>Before Treatment</em></p><p>KOLITARDA, as with other HMG-CoA reductase inhibitors, should be prescribed with caution in patients with pre-disposing factors for myopathy/rhabdomyolysis. Such factors include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; renal impairment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypothyroidism</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; personal or family history of hereditary muscular disorders</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alcohol abuse</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; age &gt;70 years</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; situations where an increase in plasma levels may occur (see sections 4.2, 4.5 and 5.2)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; concomitant use of fibrates.</p><p>In such patients the risk of treatment should be considered in relation to possible benefit and clinical monitoring is recommended. If CK levels are significantly elevated at baseline (&gt;5xULN) treatment should not be started.</p><p><em>Whilst on Treatment</em></p><p>Patients should be asked to report inexplicable muscle pain, weakness or cramps immediately, particularly if associated with malaise or fever. CK levels should be measured in these patients. Therapy should be discontinued if CK levels are markedly elevated (&gt;5xULN) or if muscular symptoms are severe and cause daily discomfort (even if CK levels are &le;5xULN). If symptoms resolve and CK levels return to normal, then consideration should be given to re-introducing KOLITARDA&nbsp;&nbsp; or an alternative HMG-CoA reductase inhibitor at the lowest dose with close monitoring. Routine monitoring of CK levels in asymptomatic patients is not warranted. There have been very rare reports of an immune-mediated necrotising myopathy (IMNM) during or after treatment with statins, including rosuvastatin. IMNM is clinically characterised by proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment.</p><p>In clinical trials, there was no evidence of increased skeletal muscle effects in the small number of patients dosed with KOLITARDA and concomitant therapy. However, an increase in the incidence of myositis and myopathy has been seen in patients receiving other HMG-CoA reductase inhibitors together with fibric acid derivatives including gemfibrozil, ciclosporin, nicotinic acid, azole antifungals, protease inhibitors and macrolide antibiotics. Gemfibrozil increases the risk of myopathy when given concomitantly with some HMG-CoA reductase inhibitors. Therefore, the combination of KOLITARDA and gemfibrozil is not recommended. The benefit of further alterations in lipid levels by the combined use of KOLITARDA with fibrates or niacin should be carefully weighed against the potential risks of such combinations. The 40 mg dose is contraindicated with concomitant use of a fibrate (see sections 4.5 and 4.8).</p><p>KOLITARDA must not be co-administered with systemic formulations of fusidic acid or within 7 days of stopping fusidic acid treatment. In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving fusidic acid and statins in combination (see section 4.5). Patients should be advised to seek medical advice immediately if they experience any symptoms of muscle weakness, pain or tenderness. Statin therapy may be re-introduced seven days after the last dose of fusidic acid. In exceptional circumstances, where prolonged systemic fusidic acid is needed, e.g. for the treatment of severe infections, the need for co-administration of KOLITARDA and fusidic acid should only be considered on a case by case basis and under close medical supervision.</p><p>KOLITARDA&nbsp;&nbsp; should not be used in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders; or uncontrolled seizures).</p><p><u>Severe Cutaneous Adverse Reactions</u></p><p>Severe cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS), which could be life-threatening or fatal, have been reported with rosuvastatin (see section 4.8). At the time of prescription, patients should be advised of the signs and symptoms of severe skin reactions and be closely monitored. If signs and symptoms suggestive of this reaction appear, KOLITARDA should be discontinued immediately and an alternative treatment should be considered.</p><p>If the patient has developed a serious reaction such as SJS or DRESS with the use of KOLITARDA, treatment with KOLITARDA&nbsp;&nbsp; must not be restarted in this patient at any time.</p><p><u>Liver Effects</u></p><p>As with other HMG-CoA reductase inhibitors, KOLITARDA&nbsp;&nbsp; should be used with caution in patients who consume excessive quantities of alcohol and/or have a history of liver disease.</p><p>It is recommended that liver function tests be carried out prior to, and 3 months following, the initiation of treatment. KOLITARDA&nbsp;&nbsp; should be discontinued or the dose reduced if the level of serum transaminases is greater than 3 times the upper limit of normal. The reporting rate for serious hepatic events (consisting mainly of increased hepatic transaminases) in post-marketing use is higher at the 40 mg dose.</p><p>In patients with secondary hypercholesterolemia caused by hypothyroidism or nephrotic syndrome, the underlying disease should be treated prior to initiating therapy with KOLITARDA.</p><p><u>Race</u></p><p>Pharmacokinetic studies show an increase in exposure in Asian subjects compared with Caucasians (see sections 4.2, 4.3 and 5.2).</p><p><u>Protease Inhibitors</u></p><p>Increased systemic exposure to rosuvastatin has been observed in subjects receiving rosuvastatin concomitantly with various protease inhibitors in combination with ritonavir. Consideration should be given both to the benefit of lipid lowering by use of KOLITARDA in HIV patients receiving protease inhibitors and the potential for increased rosuvastatin plasma concentrations when initiating and up titrating KOLITARDA doses in patients treated with protease inhibitors. The concomitant use with certain protease inhibitors is not recommended unless the dose of KOLITARDA&nbsp;&nbsp; is adjusted. (See sections 4.2 and 4.5).</p><p><u>Lactose Intolerance</u></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p><u>Interstitial Lung Disease</u></p><p>Exceptional cases of interstitial lung disease have been reported with some statins, especially with long-term therapy (see section 4.8). Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.</p><p><u>Diabetes Mellitus</u></p><p>Some evidence suggests that statins as a class raise blood glucose and in some patients, at high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping statin treatment. Patients at risk (fasting glucose 5.6 to 6.9 mmol/l, BMI &gt;30 kg/m<sup>2</sup>, raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines.</p><p>In the JUPITER study, the reported overall frequency of diabetes mellitus was 2.8% in rosuvastatin and 2.3% in placebo, mostly in patients with fasting glucose 5.6 to 6.9 mmol/l.</p><p><u>Paediatric Population</u></p><p>The evaluation of linear growth (height), weight, BMI (body mass index), and secondary characteristics of sexual maturation by Tanner staging in paediatric patients 6 to 17 years of age taking rosuvastatin is limited to a two-year period. After two years of study treatment, no effect on growth, weight, BMI or sexual maturation was detected (see section 5.1).</p><p>In a clinical trial of children and adolescents receiving rosuvastatin for 52 weeks, CK elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently compared to observations in clinical trials in adults (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effect of co-administered medicinal products on rosuvastatin</u></p><p><em>Transporter protein inhibitors</em></p><p>Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter OATP1B1 and efflux transporter BCRP. Concomitant administration of KOLITARDA&nbsp;&nbsp; with medicinal products that are inhibitors of these transporter proteins may result in increased rosuvastatin plasma concentrations and an increased risk of myopathy (see sections 4.2, 4.4 and 4.5 Table 1).</p><p><em>Ciclosporin:</em>&nbsp;During concomitant treatment with KOLITARDA&nbsp;&nbsp; and ciclosporin, rosuvastatin AUC values were on average 7 times higher than those observed in healthy volunteers (see Table 1). KOLITARDA&nbsp;&nbsp; is contraindicated in patients receiving concomitant ciclosporin (see section 4.3). Concomitant administration did not affect plasma concentrations of ciclosporin.</p><p><em>Protease inhibitors:</em>&nbsp;Although the exact mechanism of interaction is unknown, concomitant protease inhibitor use may strongly increase rosuvastatin exposure (see Table 1). For instance, in a pharmacokinetic study, co-administration of 10 mg rosuvastatin and a combination product of two protease inhibitors (300 mg atazanavir/100 mg ritonavir) in healthy volunteers was associated with an approximately three-fold and seven-fold increase in rosuvastatin AUC and C<sub>max</sub>&nbsp;respectively. The concomitant use of KOLITARDA&nbsp;&nbsp; and some protease inhibitor combinations may be considered after careful consideration of KOLITARDA&nbsp;&nbsp; dose adjustments based on the expected increase in rosuvastatin exposure (see sections 4.2, 4.4 and 4.5 Table 1).</p><p><em>Gemfibrozil and other lipid-lowering products</em></p><p>Concomitant use of KOLITARDA&nbsp;&nbsp; and gemfibrozil resulted in a 2-fold increase in rosuvastatin C<sub>max</sub>&nbsp;and AUC (see section 4.4).</p><p>Based on data from specific interaction studies no pharmacokinetic relevant interaction with fenofibrate is expected, however a pharmacodynamics interaction may occur. Gemfibrozil, fenofibrate, other fibrates and lipid lowering doses (&gt; or equal to 1 g/day) of niacin (nicotinic acid) increase the risk of myopathy when given concomitantly with HMG-CoA reductase inhibitors, probably because they can produce myopathy when given alone. The 40 mg dose is contraindicated with concomitant use of a fibrate (see sections 4.3 and 4.4). These patients should also start with the 5 mg dose.</p><p><em>Ezetimibe</em></p><p>Concomitant use of 10 mg KOLITARDA&nbsp;&nbsp; and 10 mg ezetimibe resulted in a 1.2-fold increase in AUC of rosuvastatin in hypercholesterolemia subjects (Table 1). A pharmacodynamics interaction, in terms of adverse effects, between KOLITARDA&nbsp;&nbsp; and ezetimibe cannot be ruled out (see section 4.4).</p><p><em>Antacid</em></p><p>The simultaneous dosing of KOLITARDA&nbsp;&nbsp; with an antacid suspension containing aluminium and magnesium hydroxide resulted in a decrease in rosuvastatin plasma concentration of approximately 50%. This effect was mitigated when the antacid was dosed 2 hours after KOLITARDA. The clinical relevance of this interaction has not been studied.</p><p><em>Erythromycin</em></p><p>Concomitant use of KOLITARDA&nbsp; &nbsp;and erythromycin resulted in a 20% decrease in AUC and a 30% decrease in C<sub>max</sub>&nbsp;of rosuvastatin. This interaction may be caused by the increase in gut motility caused by erythromycin.</p><p><em>Cytochrome P450 enzymes</em></p><p>Results from&nbsp;<em>in vitro</em>&nbsp;and&nbsp;<em>in vivo</em>&nbsp;studies show that rosuvastatin is neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. In addition, rosuvastatin is a poor substrate for these isoenzymes. Therefore, drug interactions resulting from cytochrome P450-mediated metabolism are not expected. No clinically relevant interactions have been observed between rosuvastatin and either fluconazole (an inhibitor of CYP2C9 and CYP3A4) or ketoconazole (an inhibitor of CYP2A6 and CYP3A4).</p><p><em>Interactions requiring rosuvastatin dose adjustments (see also Table 1):</em></p><p>When it is necessary to co-administer KOLITARDA&nbsp;&nbsp; with other medicinal products known to increase exposure to rosuvastatin, doses of KOLITARDA&nbsp;&nbsp; should be adjusted. Start with a 5 mg once daily dose of KOLITARDA&nbsp;&nbsp; if the expected increase in exposure (AUC) is approximately 2-fold or higher. The maximum daily dose of KOLITARDA&nbsp;&nbsp; should be adjusted so that the expected rosuvastatin exposure would not likely exceed that of a 40 mg daily dose of KOLITARDA&nbsp;&nbsp; taken without interacting medicinal products, for example a 20 mg dose of KOLITARDA&nbsp;&nbsp; with gemfibrozil (1.9-fold increase), and a 10 mg dose of KOLITARDA&nbsp;&nbsp; with combination ritonavir/atazanavir (3.1-fold increase).</p><p>If medicinal product is observed to increase rosuvastatin AUC less than 2-fold, the starting dose need not be decreased but caution should be taken if increasing the KOLITARDA&nbsp;&nbsp; dose above 20mg.</p><p><strong>Table 1 Effect of co-administered medicinal products on rosuvastatin exposure (AUC; in order of decreasing magnitude) from published clinical trials.</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:623px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>2-fold or greater than 2-fold increase in AUC of rosuvastatin</strong></p></td></tr><tr><td><p><strong>Interacting drug dose regimen</strong></p></td><td><p><strong>Rosuvastatin dose regimen</strong></p></td><td><p><strong>Change in rosuvastatin AUC*</strong></p></td></tr><tr><td><p>Sofosbuvir/velpatasvir/voxilaprevir (400 mg-100 mg-100 mg) + Voxilaprevir (100 mg) once daily for 15 days</p></td><td><p>10mg single dose</p></td><td><p>7.4 -fold &uarr;</p></td></tr><tr><td><p>Ciclosporin 75 mg BID to 200 mg BID, 6 months</p></td><td><p>10 mg OD, 10 days</p></td><td><p>7.1-fold &uarr;</p></td></tr><tr><td><p>Darolutamide 600 mg BID, 5 days</p></td><td><p>5mg, single dose</p></td><td><p>5.2-fold &uarr;</p></td></tr><tr><td><p>Regorafenib 160 mg, OD, 14 days</p></td><td><p>5 mg, single dose</p></td><td><p>3.8-fold &uarr;</p></td></tr><tr><td><p>Atazanavir 300 mg/ritonavir 100 mg OD, 8 days</p></td><td><p>10 mg, single dose</p></td><td><p>3.1-fold &uarr;</p></td></tr><tr><td><p>Velpatasvir 100 mg OD</p></td><td><p>10 mg, single dose</p></td><td><p>2.7-fold &uarr;</p></td></tr><tr><td><p>Ombitasvir 25 mg/paritaprevir 150 mg/ Ritonavir 100 mg OD/ dasabuvir 400 mg BID, 14 days</p></td><td><p>5 mg, single dose</p></td><td><p>2.6-fold &uarr;</p></td></tr><tr><td><p>Grazoprevir 200 mg/elbasvir 50 mg OD, 11 days</p></td><td><p>10 mg, single dose</p></td><td><p>2.3-fold &uarr;</p></td></tr><tr><td><p>Glecaprevir 400 mg/pibrentasvir 120 mg OD, 7 days</p></td><td><p>5 mg OD, 7 days</p></td><td><p>2.2-fold &uarr;</p></td></tr><tr><td><p>Lopinavir 400 mg/ritonavir 100 mg BID, 17 days</p></td><td><p>20 mg OD, 7 days</p></td><td><p>2.1-fold &uarr;</p></td></tr><tr><td><p>Clopidogrel 300 mg loading, followed by 75 mg at 24 hours</p></td><td><p>20 mg, single dose</p></td><td><p>2-fold &uarr;</p></td></tr><tr><td><p>Gemfibrozil 600 mg BID, 7 days</p></td><td><p>80 mg, single dose</p></td><td><p>1.9-fold &uarr;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Less than 2-fold increase in AUC of rosuvastatin</strong></p></td></tr><tr><td><p><strong>Interacting drug dose regimen</strong></p></td><td><p><strong>Rosuvastatin dose regimen</strong></p></td><td><p><strong>Change in rosuvastatin AUC<sup>*</sup></strong></p></td></tr><tr><td><p>Eltrombopag 75 mg OD, 5 days</p></td><td><p>10 mg, single dose</p></td><td><p>1.6-fold &uarr;</p></td></tr><tr><td><p>Darunavir 600 mg/ritonavir 100 mg BID, 7 days</p></td><td><p>10 mg OD, 7 days</p></td><td><p>1.5-fold &uarr;</p></td></tr><tr><td><p>Tipranavir 500 mg/ritonavir 200 mg BID, 11 days</p></td><td><p>10 mg, single dose</p></td><td><p>1.4-fold &uarr;</p></td></tr><tr><td><p>Dronedarone 400 mg BID</p></td><td><p>Not available</p></td><td><p>1.4-fold &uarr;</p></td></tr><tr><td><p>Itraconazole 200 mg OD, 5 days</p></td><td><p>10 mg, single dose</p></td><td><p>**1.4-fold &uarr;</p></td></tr><tr><td><p>Ezetimibe 10 mg OD, 14 days</p></td><td><p>10 mg, OD, 14 days</p></td><td><p>**1.2-fold &uarr;</p></td></tr><tr><td colspan="3"><p><strong>Decrease in AUC of rosuvastatin</strong></p></td></tr><tr><td><p><strong>Interacting drug dose regimen</strong></p></td><td><p><strong>Rosuvastatin dose regimen</strong></p></td><td><p><strong>Change in rosuvastatin AUC<sup>*</sup></strong></p></td></tr><tr><td><p>Erythromycin 500 mg QID, 7 days</p></td><td><p>80 mg, single dose</p></td><td><p>20% &darr;</p></td></tr><tr><td><p>Baicalin 50 mg TID, 14 days</p></td><td><p>20 mg, single dose</p></td><td><p>47% &darr;</p></td></tr><tr><td colspan="3" style="vertical-align:top">&nbsp;</td></tr></tbody></table><p><sup>*</sup>Data given as x-fold change represent a simple ratio between co-administration and rosuvastatin alone. Data given as % change represent % difference relative to rosuvastatin alone.</p><p>Increase is indicated as &ldquo;&uarr;<u>&rdquo;,</u>&nbsp;decrease as &ldquo;&darr;&rdquo;.</p><p><sup>**</sup>Several interaction studies have been performed at different KOLITARDA&nbsp;&nbsp; dosages, the table shows the most significant ratio</p><p>AUC = area under curve; OD = once daily; BID = twice daily; TID = three times daily; QID = four times daily</p><p>The following medical product/combinations did not have a clinically significant effect on the AUC ratio of rosuvastatin at coadministration:</p><p>Aleglitazar 0.3 mg 7 days dosing; Fenofibrate 67 mg 7 days TID dosing; Fluconazole 200mg 11 days OD dosing; Fosamprenavir 700 mg/ritonavir 100 mg 8 days BID dosing; Ketoconazole 200 mg 7 days BID dosing; Rifampin 450 mg 7 days OD dosing; Silymarin 140 mg 5 days TID dosing.</p><p><u>Effect of rosuvastatin on co-administered medicinal products</u></p><p><em>Vitamin K antagonists</em></p><p>As with other HMG-CoA reductase inhibitors, the initiation of treatment or dosage up-titration of KOLITARDA&nbsp;&nbsp; in patients treated concomitantly with vitamin K antagonists (e.g. warfarin or another coumarin anticoagulant) may result in an increase in International Normalised Ratio (INR). Discontinuation or down-titration of KOLITARDA&nbsp;&nbsp; may result in a decrease in INR. In such situations, appropriate monitoring of INR is desirable.</p><p><em>Oral contraceptive/hormone replacement therapy (HRT)</em></p><p>Concomitant use of KOLITARDA&nbsp;&nbsp; and an oral contraceptive resulted in an increase in ethinyl estradiol and norgestrel AUC of 26% and 34%, respectively. These increased plasma levels should be considered when selecting oral contraceptive doses. There are no pharmacokinetic data available in subjects taking concomitant KOLITARDA&nbsp;&nbsp; and HRT, therefore, a similar effect cannot be excluded. However, the combination has been extensively used in women in clinical trials and was well tolerated.</p><p><u>Other medicinal products:</u></p><p><em>Digoxin</em></p><p>Based on data from specific interaction studies no clinically relevant interaction with digoxin is expected.</p><p><em>Fusidic Acid</em></p><p>Interaction studies with rosuvastatin and fusidic acid have not been conducted. The risk of myopathy, including rhabdomyolysis may be increased by the concomitant administration of systemic fusidic acid with statins. The mechanism of this interaction (whether it is pharmacodynamic or pharmacokinetic, or both) is yet unknown. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination.</p><p>If treatment with systemic fusidic acid is necessary, KOLITARDA&nbsp;&nbsp; treatment should be discontinued throughout the duration of the fusidic acid treatment.&nbsp;<strong>Also see section 4.4.</strong></p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults. The extent of interactions in the paediatric population is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>KOLITARDA is not recommended during pregnancy unless the benefits of using KOLITARDA outweighs the risks. The benefits of statin might include prevention of serious or potentially fatal events of very high-risk pregnant women.</p><p>Animal studies provide limited evidence of reproductive toxicity (see section 5.3). if a patient&nbsp; becomes pregnant during use of this product, benefits and risks profile should be assessed and individual judgment should be made.</p><p><u>Breast-feeding</u></p><p>Rosuvastatin is excreted in the milk of rats. There are no data with respect to excretion in milk in humans (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies to determine the effect of KOLITARDA&nbsp; &nbsp;on the ability to drive and use machines have not been conducted. However, based on its pharmacodynamic properties, KOLITARDA&nbsp; &nbsp;is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that dizziness may occur during treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions seen with KOLITARDA&nbsp;&nbsp; are generally mild and transient. In controlled clinical trials, less than 4% of KOLITARDA-treated patients were withdrawn due to adverse reactions.</p><p>Tabulated list of adverse reactions</p><p>Based on data from clinical studies and extensive post-marketing experience, the following table presents the adverse reaction profile for rosuvastatin. Adverse reactions listed below are classified according to frequency and system organ class (SOC).</p><p>The frequencies of adverse reactions are ranked according to the following convention: Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to &lt;1/1000); Very rare (&lt;1/10,000); Not known (cannot be estimated from the available data).</p><p><strong>Table 2. Adverse reactions based on data from clinical studies and post-marketing experience</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:623px"><tbody><tr><td><p><strong>System organ class</strong></p></td><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td><td><p><strong>Very rare</strong></p></td><td><p><strong>Not known</strong></p></td></tr><tr><td><p><strong>Blood and lymphatic system disorders</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Thrombocytopenia</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p><strong>Immune system disorders</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Hypersensitivity reactions including angioedema</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p><strong>Endocrine disorders</strong></p></td><td><p>Diabetes mellitus<sup>1</sup></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p><strong>Psychiatric disorders</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Depression</p></td></tr><tr><td><p><strong>Nervous system disorders</strong></p></td><td><p>Headache</p><p>Dizziness</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Polyneuropathy</p><p>Memory loss</p></td><td><p>Peripheral neuropathy</p><p>Sleep disturbances (including insomnia and nightmares)</p></td></tr><tr><td><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Cough</p><p>Dyspnoea</p></td></tr><tr><td><p><strong>Gastro-intestinal disorders</strong></p></td><td><p>Constipation</p><p>Nausea</p><p>Abdominal pain</p></td><td>&nbsp;</td><td><p>Pancreatitis</p></td><td>&nbsp;</td><td><p>Diarrhoea</p></td></tr><tr><td><p><strong>Hepatobiliary disorders</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Increased hepatic transaminases</p></td><td><p>Jaundice</p><p>Hepatitis</p></td><td>&nbsp;</td></tr><tr><td><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td>&nbsp;</td><td><p>Pruritus</p><p>Rash</p><p>Urticaria</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Stevens-Johnson syndrome</p><p>Drug reaction with eosinophilia and systemic symptoms (DRESS)</p></td></tr><tr><td><p><strong>Musculo-skeletal and connective tissue disorders</strong></p></td><td><p>Myalgia</p></td><td>&nbsp;</td><td><p>Myopathy (including myositis)</p><p>Rhabdomyolysis</p><p>Lupus-like syndrome</p><p>Muscle rupture</p></td><td><p>Arthralgia</p></td><td><p>Tendon disorders, sometimes complicated by rupture</p><p>Immune-mediated necrotising myopathy</p></td></tr><tr><td><p><strong>Renal and urinary disorders</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Haematuria</p></td><td>&nbsp;</td></tr><tr><td><p><strong>Reproductive system and breast disorders</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Gynaecomastia</p></td><td>&nbsp;</td></tr><tr><td><p><strong>General disorders and administration site conditions</strong></p></td><td><p>Asthenia</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Oedema</p></td></tr><tr><td colspan="6"><p><sup>1&nbsp;</sup>Frequency will depend on the presence or absence of risk factors (fasting blood glucose &ge; 5.6 mmol/L, BMI &gt;30 kg/m<sup>2</sup>, raised triglycerides, history of hypertension).</p></td></tr></tbody></table><p>As with other HMG-CoA reductase inhibitors, the incidence of adverse drug reactions tends to be dose dependent.</p><p><em>Renal effects</em></p><p>Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with KOLITARDA. Shifts in urine protein from none or trace to ++ or more were seen in &lt;1% of patients at some time during treatment with 10 and 20 mg, and in approximately 3% of patients treated with 40 mg. A minor increase in shift from none or trace to + was observed with the 20 mg dose. In most cases, proteinuria decreases or disappears spontaneously on continued therapy. Review of data from clinical trials and post-marketing experience to date has not identified a causal association between proteinuria and acute or progressive renal disease.</p><p>Haematuria has been observed in patients treated with KOLITARDA&nbsp;&nbsp; and clinical trial data show that the occurrence is low.</p><p><em>Skeletal muscle effects</em></p><p>Effects on skeletal muscle e.g. myalgia, myopathy (including myositis) and, rarely, rhabdomyolysis with and without acute renal failure have been reported in KOLITARDA-treated patients with all doses and in particular with doses &gt; 20 mg.</p><p>A dose-related increase in CK levels has been observed in patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient. If CK levels are elevated (&gt;5xULN), treatment should be discontinued (see section 4.4).</p><p><em>Liver effects</em></p><p>As with other HMG-CoA reductase inhibitors, a dose-related increase in transaminases has been observed in a small number of patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient.</p><p>The following adverse events have been reported with some statins:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sexual dysfunction.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exceptional cases of interstitial lung disease, especially with long term therapy (see section 4.4).</p><p>The reporting rates for rhabdomyolysis, serious renal events and serious hepatic events (consisting mainly of increased hepatic transaminases) is higher at the 40 mg dose.</p><p><u>Paediatric population</u></p><p>Creatine kinase elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently in a 52-week clinical trial of children and adolescents compared to adults (see section 4.4). In other respects, the safety profile of rosuvastatin was similar in children and adolescents compared to adults.</p><p><strong>To report any side effect(s): </strong></p><p>&sect;&nbsp;&nbsp; <strong><em>Saudi Arabia:</em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:378px"><tbody><tr><td style="vertical-align:top"><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&sect;&nbsp;&nbsp; <strong><em>Other GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment in the event of overdose. In the event of overdose, the patient should be treated symptomatically and supportive measures instituted as required. Liver function and CK levels should be monitored. Hemodialysis is unlikely to be of benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group:&nbsp;HMG-CoA reductase inhibitors. ATC<strong> </strong>code<strong>:&nbsp;</strong>C10A A07</p><p><u>Mechanism of action</u></p><p>Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for cholesterol. The primary site of action of rosuvastatin is the liver, the target organ for cholesterol lowering.</p><p>Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.</p><p><u>Pharmacodynamic effects</u></p><p>KOLITARDA&nbsp;&nbsp; reduces elevated LDL-cholesterol, total cholesterol and triglycerides and increases HDL-cholesterol. It also lowers ApoB, non-HDL-C, VLDL-C, VLDL-TG and increases ApoA-I (see Table 3). KOLITARDA&nbsp;&nbsp; also lowers the LDL-C/HDL-C, total C/HDL-C and non-HDL-C/HDL-C and the ApoB/ApoA-I ratios.</p><p><strong>Table 3 Dose response in patients with primary hypercholesterolaemia (type IIa and IIb) (adjusted mean percent change from baseline)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:623px"><tbody><tr><td><p><strong>Dose</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>LDL-C</strong></p></td><td><p><strong>Total-C</strong></p></td><td><p><strong>HDL-C</strong></p></td><td><p><strong>TG</strong></p></td><td><p><strong>nonHDL-C</strong></p></td><td><p><strong>ApoB</strong></p></td><td><p><strong>ApoA-I</strong></p></td></tr><tr><td><p>Placebo</p></td><td><p>13</p></td><td><p>-7</p></td><td><p>-5</p></td><td><p>3</p></td><td><p>-3</p></td><td><p>-7</p></td><td><p>-3</p></td><td><p>0</p></td></tr><tr><td><p>5</p></td><td><p>17</p></td><td><p>-45</p></td><td><p>-33</p></td><td><p>13</p></td><td><p>-35</p></td><td><p>-44</p></td><td><p>-38</p></td><td><p>4</p></td></tr><tr><td><p>10</p></td><td><p>17</p></td><td><p>-52</p></td><td><p>-36</p></td><td><p>14</p></td><td><p>-10</p></td><td><p>-48</p></td><td><p>-42</p></td><td><p>4</p></td></tr><tr><td><p>20</p></td><td><p>17</p></td><td><p>-55</p></td><td><p>-40</p></td><td><p>8</p></td><td><p>-23</p></td><td><p>-51</p></td><td><p>-46</p></td><td><p>5</p></td></tr><tr><td><p>40</p></td><td><p>18</p></td><td><p>-63</p></td><td><p>-46</p></td><td><p>10</p></td><td><p>-28</p></td><td><p>-60</p></td><td><p>-54</p></td><td><p>0</p></td></tr></tbody></table><p>A therapeutic effect is obtained within 1 week following treatment initiation and 90% of maximum response is achieved in 2 weeks. The maximum response is usually achieved by 4 weeks and is maintained after that.</p><p><u>Clinical efficacy and safety</u></p><p>KOLITARDA&nbsp;&nbsp; is effective in adults with hypercholesterolemia, with and without hypertriglyceridemia, regardless of race, sex or age and in special populations such as diabetics or patients with familial hypercholesterolemia.</p><p>From pooled phase III data, KOLITARDA&nbsp;&nbsp; has been shown to be effective at treating the majority of patients with type IIa and IIb hypercholesterolemia (mean baseline LDL-C about 4.8 mmol/L) to recognised European Atherosclerosis Society (EAS; 1998) guideline targets; about 80% of patients treated with 10 mg reached the EAS targets for LDL-C levels (&lt;3 mmol/L).</p><p>In a large study, 435 patients with heterozygous familial hypercholesterolaemia were given KOLITARDA&nbsp;&nbsp; from 20 mg to 80 mg in a force-titration design. All doses showed a beneficial effect on lipid parameters and treatment to target goals. Following titration to a daily dose of 40 mg (12 weeks of treatment), LDL-C was reduced by 53%. Thirty-three percent (33%) of patients reached EAS guidelines for LDL-C levels (&lt;3 mmol/L).</p><p>In a force-titration, open label trial, 42 patients (including 8 paediatric patients) with homozygous familial hypercholesterolaemia were evaluated for their response to KOLITARDA&nbsp;&nbsp; 20 &ndash; 40 mg. In the overall population, the mean LDL-C reduction was 22%.</p><p>In clinical studies with a limited number of patients, KOLITARDA&nbsp;&nbsp; has been shown to have additive efficacy in lowering triglycerides when used in combination with fenofibrate and in increasing HDL-C levels when used in combination with niacin (see section 4.4).</p><p>In a multi-centre, double-blind, placebo-controlled clinical study (METEOR), 984 patients between 45 and 70 years of age and at low risk for coronary heart disease (defined as Framingham risk &lt;10% over 10 years), with a mean LDL-C of 4.0 mmol/L (154.5 mg/dL), but with subclinical atherosclerosis (detected by Carotid Intima Media Thickness) were randomised to 40 mg rosuvastatin once daily or placebo for 2 years. Rosuvastatin significantly slowed the rate of progression of the maximum CIMT for the 12 carotid artery sites compared to placebo by -0.0145 mm/year [95% confidence interval -0.0196, -0.0093; p&lt;0.0001]. The change from baseline was -0.0014 mm/year (-0.12%/year (non-significant)) for rosuvastatin compared to a progression of +0.0131 mm/year (1.12%/year (p&lt;0.0001)) for placebo. No direct correlation between CIMT decrease and reduction of the risk of cardiovascular events has yet been demonstrated. The population studied in METEOR is low risk for coronary heart disease and does not represent the target population of KOLITARDA&nbsp;&nbsp; 40 mg. The 40 mg dose should only be prescribed in patients with severe hypercholesterolemia at high cardiovascular risk (see section 4.2).</p><p>In the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study, the effect of rosuvastatin on the occurrence of major atherosclerotic cardiovascular disease events was assessed in 17,802 men (&ge;50 years) and women (&ge;60 years).</p><p>Study participants were randomly assigned to placebo (n=8901) or rosuvastatin 20 mg once daily (n=8901) and were followed for a mean duration of 2 years.</p><p>LDL-cholesterol concentration was reduced by 45% (p&lt;0.001) in the rosuvastatin group compared to the placebo group.</p><p>In a post-hoc analysis of a high-risk subgroup of subjects with a baseline Framingham risk score &gt;20% (1558 subjects) there was a significant reduction in the combined end-point of cardiovascular death, stroke and myocardial infarction (p=0.028) on rosuvastatin treatment versus placebo. The absolute risk reduction in the event rate per 1000 patient-years was 8.8. Total mortality was unchanged in this high-risk group (p=0.193). In a post-hoc analysis of a high-risk subgroup of subjects (9302 subjects total) with a baseline SCORE risk &ge;5% (extrapolated to include subjects above 65 yrs) there was a significant reduction in the combined end-point of cardiovascular death, stroke and myocardial infarction (p=0.0003) on rosuvastatin treatment versus placebo. The absolute risk reduction in the event rate was 5.1 per 1000 patient-years. Total mortality was unchanged in this high-risk group (p=0.076).</p><p>In the JUPITER trial, there were 6.6% of rosuvastatin and 6.2% of placebo subjects who discontinued use of study medication due to an adverse event. The most common adverse events that led to treatment discontinuation were: myalgia (0.3% rosuvastatin, 0.2% placebo), abdominal pain (0.03% rosuvastatin, 0.02% placebo) and rash (0.02% rosuvastatin, 0.03% placebo). The most common adverse events at a rate greater than or equal to placebo were urinary tract infection (8.7% rosuvastatin, 8.6% placebo), nasopharyngitis (7.6% rosuvastatin, 7.2% placebo), back pain (7.6% rosuvastatin, 6.9% placebo) and myalgia (7.6% rosuvastatin, 6.6% placebo).</p><p><u>Paediatric population</u></p><p>In a double-blind, randomised, multi-centre, placebo-controlled, 12-week study (n=176, 97 male and 79 female) followed by a 40-week (n=173, 96 male and 77 female), open-label, rosuvastatin dose-titration phase, patients 10 to 17 years of age (Tanner stage II-V, females at least 1-year post-menarche) with heterozygous familial hypercholesterolemia received rosuvastatin 5, 10 or 20 mg or placebo daily for 12 weeks and then all received rosuvastatin daily for 40 weeks. At study entry, approximately 30% of the patients were 10 to 13 years and approximately 17%, 18%, 40%, and 25% were Tanner stage II, III, IV, and V, respectively.</p><p>LDL-C was reduced 38.3%, 44.6%, and 50.0% by rosuvastatin 5, 10 and 20 mg, respectively, compared to 0.7% for placebo.</p><p>At the end of the 40-week, open-label, titration to goal, dosing up to a maximum of 20 mg once daily, 70 of 173 patients (40.5%) had achieved the LDL-C goal of less than 2.8 mmol/L.</p><p>After 52 weeks of study treatment, no effect on growth, weight, BMI or sexual maturation was detected (see section 4.4). This trial (n=176) was not suited for comparison of rare adverse drug events.</p><p>Rosuvastatin was also studied in a 2-year open-label, titration-to-goal study in 198 children with heterozygous familial hypercholesterolemia aged 6 to 17 years (88 male and 110 female, Tanner stage &lt;II-V). The starting dose for all patients was 5 mg rosuvastatin once daily. Patients aged 6 to 9 years (n=64) could titrate to a maximum dose of 10 mg once daily and patients aged 10 to 17 years (n=134) to a maximum dose of 20 mg once daily.</p><p>After 24 months of treatment with rosuvastatin, the LS mean percent reduction from the baseline value in LDL-C was -43% (Baseline: 236 mg/dL, Month 24: 133 mg/dL). For each age group, the LS mean percent reductions from baseline values in LDL-C were -43% (Baseline: 234 mg/dL, Month 24: 124 mg/dL), -45% (Baseline: 234 mg/dL, Month 24: 124 mg/dL) and -35% (Baseline: 241 mg/dL, Month 24: 153 mg/dL) in the 6 to &lt;10, 10 to &lt;14, and 14 to &lt;18 age groups, respectively.</p><p>Rosuvastatin 5 mg, 10 mg, and 20 mg also achieved statistically significant mean changes from baseline for the following secondary lipid and lipoprotein variables: HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, TG/HDL-C, non-HDL C/HDL-C, ApoB, ApoB/ApoA-1. These changes were each in the direction of improved lipid responses and were sustained over 2 years.</p><p>No effect on growth, weight, BMI or sexual maturation was detected after 24 months of treatment (see section 4.4).</p><p>Rosuvastatin was studied in a randomised, double-blind, placebo-controlled, multi-centre, cross-over study with 20 mg once daily versus placebo in 14 children and adolescents (aged from 6 to 17 years) with homozygous familial hypercholesterolemia. The study included an active 4-week dietary lead-in phase during which patients were treated with rosuvastatin 10 mg, a cross-over phase that consisted of a 6-week treatment period with rosuvastatin 20 mg preceded or followed by a 6-week placebo treatment period, and a 12-week maintenance phase during which all patients were treated with rosuvastatin 20 mg. Patients who entered the study on ezetimibe or apheresis therapy continued the treatment throughout the entire study.</p><p>A statistically significant (p=0.005) reduction in LDL-C (22.3%, 85.4 mg/dL or 2.2 mmol/L) was observed following 6 weeks of treatment with rosuvastatin 20 mg versus placebo. Statistically significant reductions in Total-C (20.1%, p=0.003), non-HDL-C (22.9%, p=0.003) and ApoB (17.1%, p=0.024) were observed. Reductions were also seen in TG, LDL-C/HDL-C, Total-C/HDL-C, non-HDL-C/HDL-C and ApoB/ApoA-1 following 6 weeks of treatment with rosuvastatin 20 mg versus placebo. The reduction in LDL-C after 6 weeks of treatment with rosuvastatin 20 mg following 6 weeks of treatment with placebo was maintained over 12 weeks of continuous therapy. One patient had a further reduction in LDL-C (8.0%), Total-C (6.7%) and non-HDL-C (7.4%) following 6 weeks of treatment with 40 mg after up-titration.</p><p>During an extended open-label treatment in 9 of these patients with 20 mg rosuvastatin for up to 90 weeks, the LDL-C reduction was maintained in the range of -12.1% to -21.3%.</p><p>In the 7 evaluable children and adolescent patients (aged from 8 to 17 years) from the force-titration open label study with homozygous familial hypercholesterolemia (see above), the percent reduction in LDL-C (21.0%), Total-C (19.2%) and non-HDL-C (21.0%) from baseline following 6 weeks of treatment with rosuvastatin 20 mg was consistent with that observed in the aforementioned study in children and adolescents with homozygous familial hypercholesterolemia.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with rosuvastatin in all subsets of the paediatric population in the treatment of homozygous familial hypercholesterolemia, primary combined (mixed) dyslipidaemia and in the prevention of cardiovascular events (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Maximum rosuvastatin plasma concentrations are achieved approximately 5 hours after oral administration. The absolute bioavailability is approximately 20%.</p><p><u>Distribution</u></p><p>Rosuvastatin is taken up extensively by the liver which is the primary site of cholesterol synthesis and LDL-C clearance. The volume of distribution of rosuvastatin is approximately 134 L. Approximately 90% of rosuvastatin is bound to plasma proteins, mainly to albumin.</p><p><u>Metabolism</u></p><p>Rosuvastatin undergoes limited metabolism (approximately 10%).&nbsp;<em>In vitro</em>&nbsp;metabolism studies using human hepatocytes indicate that rosuvastatin is a poor substrate for cytochrome P450-based metabolism. CYP2C9 was the principal isoenzyme involved, with 2C19, 3A4 and 2D6 involved to a lesser extent. The main metabolites identified are the N-desmethyl and lactone metabolites. The N-desmethyl metabolite is approximately 50% less active than rosuvastatin whereas the lactone form is considered clinically inactive. Rosuvastatin accounts for greater than 90% of the circulating HMG-CoA reductase inhibitor activity.</p><p><u>Excretion</u></p><p>Approximately 90% of the rosuvastatin dose is excreted unchanged in the faeces (consisting of absorbed and non-absorbed active substance) and the remaining part is excreted in urine. Approximately 5% is excreted unchanged in urine. The plasma elimination half-life is approximately 19 hours. The elimination half-life does not increase at higher doses. The geometric mean plasma clearance is approximately 50 litres/hour (coefficient of variation 21.7%). As with other HMG-CoA reductase inhibitors, the hepatic uptake of rosuvastatin involves the membrane transporter OATP-C. This transporter is important in the hepatic elimination of rosuvastatin.</p><p><em>Linearity</em></p><p>Systemic exposure of rosuvastatin increases in proportion to dose. There are no changes in pharmacokinetic parameters following multiple daily doses.</p><p><u>Special populations:</u></p><p><em>Age and sex</em></p><p>There was no clinically relevant effect of age or sex on the pharmacokinetics of rosuvastatin in adults. The exposure in children and adolescents with heterozygous familial hypercholesterolemia appears to be similar to or lower than that in adult patients with dyslipidaemia (see &ldquo;Paediatric population&rdquo; below).</p><p><em>Race</em></p><p>Pharmacokinetic studies show an approximate 2-fold elevation in median AUC and C<sub>max</sub>&nbsp;in Asian subjects (Japanese, Chinese, Filipino, Vietnamese and Koreans) compared with Caucasians; Asian-Indians show an approximate 1.3-fold elevation in median AUC and Cmax. A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics between Caucasian and Black groups.</p><p>Renal insufficiency</p><p>In a study in subjects with varying degrees of renal impairment, mild to moderate renal disease had no influence on plasma concentration of rosuvastatin or the N-desmethyl metabolite. Subjects with severe impairment (CrCl &lt;30 ml/min) had a 3-fold increase in plasma concentration and a 9-fold increase in the N-desmethyl metabolite concentration compared to healthy volunteers. Steady-state plasma concentrations of rosuvastatin in subjects undergoing haemodialysis were approximately 50% greater compared to healthy volunteers.</p><p><em>Hepatic insufficiency</em></p><p>In a study with subjects with varying degrees of hepatic impairment, there was no evidence of increased exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, two subjects with Child-Pugh scores of 8 and 9 showed an increase in systemic exposure of at least 2-fold compared to subjects with lower Child-Pugh scores. There is no experience in subjects with Child-Pugh scores above 9.</p><p><em>Genetic polymorphisms</em></p><p>Disposition of HMG-CoA reductase inhibitors, including rosuvastatin, involves OATP1B1 and BCRP transporter proteins. In patients with SLCO1B1 (OATP1B1) and/or ABCG2 (BCRP) genetic polymorphisms there is a risk of increased rosuvastatin exposure. Individual polymorphisms of SLCO1B1 c.521CC and ABCG2 c.421AA are associated with a higher rosuvastatin exposure (AUC) compared to the SLCO1B1 c.521TT or ABCG2 c.421CC genotypes. This specific genotyping is not established in clinical practice, but for patients who are known to have these types of polymorphisms, a lower daily dose of KOLITARDA&nbsp;&nbsp; is recommended.</p><p><em>Paediatric population</em></p><p>Two pharmacokinetic studies with rosuvastatin (given as tablets) in paediatric patients with heterozygous familial hypercholesterolemia 10 to 17 or 6 to 17 years of age (total of 214 patients) demonstrated that exposure in paediatric patients appears comparable to or lower than that in adult patients. Rosuvastatin exposure was predictable with respect to dose and time over a 2-year period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenicity potential. Specific tests for effects on hERG have not been evaluated. Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels were as follows: In repeated-dose toxicity studies histopathologic liver changes likely due to the pharmacologic action of rosuvastatin were observed in mouse, rat, and to a lesser extent with effects in the gall bladder in dogs, but not in monkeys. In addition, testicular toxicity was observed in monkeys and dogs at higher dosages. Reproductive toxicity was evident in rats, with reduced litter sizes, litter weight and pup survival observed at maternally toxic doses, where systemic exposures were several times above the therapeutic exposure level.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate</p><p>Microcrystalline cellulose</p><p>Crospovidone</p><p>Tricalcium phosphate anhydrous granular</p><p>Magnesium stearate</p><p>Purified water</p><p>Oprady pink</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years (24 Months). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &ordm;C in the original pack to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &ordm;C in the original pack to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements, Keep out of the reach &amp; sight of children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alpha Pharma, 
Kingdom of Saudi Arabia, Rabigh
P.O. Box 23989-6704
Tel: +966 12 21 29013
For any information about this medicinal product, please contact the Regulatory affairs department of authorization holder: 
Regulatory affairs department 
RKOLITARDAh, Saudi Arabia 
Tel: +966112931722 Ex:102 - 104
Email: regulatory@alphapharma.com.sa

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>